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ABSTRACT 
 
Genomic instability is commonly associated with pathological disorders including cancer. 
The progressive accumulation of genetic abnormalities in cancer-associated genes can 
confer cellular autonomous proliferation, contributing to the oncogenic transformation. 
Although animal models have been instrumental to the understanding of the molecular 
mechanisms responsible for tumor progression, there are severe limitations for success. 
This thesis work aimed at the development of an innovative animal model that could 
recapitulate the ongoing lifelong accumulation of DNA lesions, leading to neoplastic 
transformation. To this end, the natural DNA mutating enzyme AID was fused to sequence 
specific DNA binding proteins. They were engineered to target tumor suppressor genes 
and to induce low-frequency mutagenesis in cell lines and in zebrafish. A TALE-Aid 
fusion protein was targeted to the p53 locus of mouse cell lines, and the Aid-dependent 
mutations were monitored by next-generation sequencing. The induced mutations occurred 
at a comparable frequency to those observed in Aid-induced non-immunoglobulin gene 
targets in B cells. Mutations were found mostly in the DNA binding domain of p53, 
possibly reflecting AID- hotspot residues in p53. Our approach also induced mutations that 
have not been characterized previously, and could provide further insight into p53 
dependent oncogenesis. When TALE-AID were expressed and targeted to the p53 locus of 
zebrafish embryos, the activity induced developmental abnormalities with variable 
severity, leading to both an increased mortality, and impaired ovarian maturation and 
fertility. We have developed and initially characterized a novel tool for the in vitro / in vivo 
study of the accumulation of mutations in cancer-associated genes. 
  16 
 CHAPTER 1 – INTRODUCTION  
 
1.1 GENOME INSTABILITY AND DNA DAMAGE RESPONSE 
Eukaryotic cells are constantly subjected to the effects of physical and chemical stress 
from endogenous and exogenous origins. The chemical and biochemical reactions in 
response to this stress damage macromolecules including DNA. 
The cellular DNA damage that occurs every day results in the accumulation of thousands 
of lesions (Table 1). If unrepaired, these lesions can lead to mutations and chromosomal 
aberrations, turning on oncogenes or inactivating tumor suppressor genes. Either 
mechanism increases the risk of human diseases such as cancer. Hence, the integrity of the 
genetic information is a requirement for the survival of the cell itself. To ensure genome 
integrity and faithful genome propagation, cells have evolved several mechanisms of 
damage tolerance, surveillance and repair (Figure 1). 
 
Table 1: DNA lesions generated by endogenous and environmental DNA damage. 
Spontaneous DNA 
damage  
DNA lesion generated Number of 
lesions/cell/day 
Reference 
Depurination AP sites 9,000 (Lindahl, 1972) 
Deamination dU 100 - 500 (Frederico et al., 1990; Lindahl and Nyberg, 1974) 
Alkylation 3MeA 600 (Lindahl and Barnes, 2000) 
Oxidation 8-oxo-G 20,000 (Beckman and Ames, 1997) 
UV radiation Pyirimidine dimers, (6-4) photoproducts 10
5 (Hoeijmakers, 2009) 
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1.1.1 Origin of endogenous DNA damages 
Although nature has chosen DNA as the predominant carrier of genetic information, it can 
be considered fragile due to some chemical and biological instabilities (Figure 1). N-
glycosyl bonds joining the base and sugar moiety are susceptible to spontaneous 
hydrolysis, resulting in the formation of mutagenic abasic sites (AP). Purines are more 
susceptible than pyrimidines, and it has been estimated that each human cell undergoes 
9,000 – 10,000 depurinations per day (Table 1) (Lindahl, 1972; Nakamura and Swenberg, 
1999). DNA bases are also susceptible to spontaneous deamination, with the N4 of 
cytosine (dC) and 5-methylcytosine (5mC) being the main target, leading to uracil (dU) 
and dT, respectively (Krokan et al., 2002). This hydrolytic deamination occurs 100 – 500 
times per day in human cells (Frederico et al., 1990; Lindahl and Nyberg, 1974) (Table 1), 
and 5-methylcytosine being about 5 – 10 times more reactive. 
Reactive oxygen species (ROS), exogenous or generated during normal cellular 
metabolism, also cause endogenous DNA damage. In aerobic cells, oxygen is normally 
converted to water without accumulation of reactive intermediates, yet 0.2 – 2 % is 
converted into reactive molecules, such as free radicals and peroxide (Maynard et al., 
2009). It has been estimated that approximately 20,000 bases in the DNA of each human 
cell are damaged by ROS every day (Beckman and Ames, 1997). 
Alkylation of endogenous DNA can be derived from the reactive methyl donor S-
adenosylmethionine (SAM), predominantly resulting in the formation of 3-methyladenine 
(3MeA), with a frequency of ~ 600 3MeA per day per cell (Lindahl and Barnes, 2000). 
The DNA replication process itself can be a source of genomic instability, including errors 
in DNA synthesis occurring during copying of the DNA template. The error rate of DNA 
polymerases is estimated to be one in 107 nucleotides (Kunkel and Bebenek, 2000), with 
specific regions of the genome called hotspots, having higher susceptibility to mutation 
due to their base composition. These hotspots can be encountered in repeat elements, 
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fragile sites of nucleotide repeats, and telomeric regions (Aguilera and Gomez-Gonzalez, 
2008). For example, fragile sites are characterized by nucleotide repeats (G-rich or AT 
rich) and are susceptible to the formation of hairpin structures that are prone to breakage 
and DNA damage or mutation (Durkin and Glover, 2007). 
 
 
 
Figure 1: DNA damage, DNA repair and consequences. 
DNA damage is induced by endogenous and exogenous agents and results in the insertion of modified bases, 
SSBs, DSBs and bulky adducts. Upon DNA damage, the cell can undergo transient cell cycle arrest to repair 
the lesions or, in case of extensive damage, can also undergo apoptosis. Repeated or persisted DNA damage 
causes permanent changes in the DNA sequence (mutation) or rearrangements, possibly leading to neoplasia. 
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1.1.2 Environmental DNA damage 
Aside from endogenous agents, environmental physical and chemical sources and 
biological agents, such as microorganisms (MO), can be a source of DNA damage (Figure 
1). Examples of physical genotoxic agents are ultraviolet radiation (UV) and ionizing 
radiation (IR). UV causes the formation of dimeric photoproducts between adjacent 
pyrimidine bases, cis – syn cyclobutane pyrimidine dimers (CPD) and pyrimidine (6-4) 
pyrimidone photoproducts (6-4PPs) (Pfeifer et al., 2005), with an estimated frequency of 
105 DNA lesions per cell per day (Hoeijmakers, 2009). The main genotoxic intermediate 
from IR are free radicals from the radiolysis of water, which lead to single-strand and 
double strand breaks (SSBs and DSBs respectively), as well as other DNA lesions 
(Wallace, 1998).  
Chemical compounds can be distinguished by their mode of actions on DNA. Base 
analogs, e.g. 5 - bromouracil (BU), that structurally resemble both purines and pyrimidines 
can be incorporated into DNA during replication and cause base pair changes upon strand 
recognition (Lasken and Goodman, 1984). Intercalating agents insert themselves in 
between the DNA bases, causing frameshift mutations (Dasgupta et al., 2012). 
Crosslinking agents such as psoralen, cisplatin, and mitomycin C (MMC) introduce 
covalent intra- and inter-strand bonds (Ciccia and Elledge, 2010; Rajski and Williams, 
1998). Although the direct mechanisms of action are not understood, it is thought that air 
pollution, tobacco smoke, pesticides, asbestos, and other toxins, are also source of 
exogenous DNA damage, either direct or indirect (Msiska et al., 2010; Phillips et al., 1988; 
Pope et al., 2002). 
Viral infections can also induce DNA damage. For example, chronic exposure to Hepatitis 
B Virus (HBV), Human Papillomavirus (HPV) and Epstein-Bar Virus (EBV), can lead to 
direct inactivation of the tumor protein p53 (TP53) and the retinoblastoma protein (pRB), 
allowing for the accumulation of genomic instability (Chen et al., 2014).  
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1.1.3 DNA damage response 
To counteract the accumulation of DNA lesions in a cell, the DNA damage response 
(DDR) is a network of interacting pathways that senses DNA damage and transduces this 
information to the cells to initiate a DNA repair response, in order to protect against 
transformation (Branzei and Foiani, 2005; Zhou and Elledge, 2000). Key components of 
the DDR machinery are proteins of the phosphatidylinositol 3-kinase-like protein kinase 
(PIKKs) family, ataxia telangiectasia mutated (ATM), ataxia-telangiectasia and Rad3-
related (ATR), and the DNA-dependent protein kinase (DNA-PK).  
Upon lesion recognition by sensor proteins (e.g. MRN complex and RPA / 9-1-1 complex) 
(Ciccia and Elledge, 2010; Zhou and Elledge, 2000), the transducers (either ATM or ATR) 
are recruited at the lesion and undergo auto-phosphorylation. In turn, they phosphorylate 
mediator proteins (e.g. BRCA1, 53BP1, MDC1, H2AX, TOPBP1). Posttranslational 
modifications (PTMs) of mediators induce the amplification of DDR signals by recruiting 
effector proteins to the DNA lesion (e.g. TP53, CDC25). The outcome of activating this 
network includes DNA repair, checkpoint signaling, and cell fate decision (Jackson and 
Bartek, 2009). Two major ATM/ATR targets are checkpoint kinase 1 and 2 (CHK1 and 
CHK2). CHK1 is activated primarily by ATR in response to SSBs, while CHK2 activation 
is downstream of ATM in response to DNA damaging agents that creates DSBs (Liu et al., 
2000; Stracker et al., 2009). CHK1 can then target the CDC25 family of phosphatases with 
consequent slow down of cell cycle progression (Mailand et al., 2000), while CHK2 
phosphorylates TP53 that, depending on the severity of the damage, triggers cell-cycle 
arrest, apoptosis or senescence (Chehab et al., 2000).  
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1.2 DNA REPAIR MECHANISMS 
Ensuring genome integrity, the DDR, upon DNA damage and replication stress, initiates 
either repair or processing of the stalled-replication forks to avoid fork-collapse. Evolution 
has developed multiple DNA repair mechanisms able to deal with every specific type of 
lesion (Figure 1). Five main repair mechanisms are present in mammals, with some 
overlapping specificities: base-excision repair (BER), mismatch repair (MMR), nucleotide 
excision repair (NER), homologous recombination (HR), and non-homologous end joining 
(NHEJ). 
 
1.2.1 Base excision repair  
BER is the predominant mechanism active against damage caused by cellular metabolism 
that result in single base lesions, including oxidation, alkylation, deamination and SSBs 
(reviewed by (Zharkov, 2008)). The first step is the recognition and excision of the 
damaged base by lesion-specific DNA glycosylases cleaving the N-glycosidic bond and 
producing an AP site (Lindahl, 1974). Eleven different DNA glycosylases are known to act 
on single or overlapping substrates. Although DNA glycosylases are subdivided into four 
structurally distinct super families, they share a common mode of action: flipping the base 
out of the DNA helix into a catalytic pocket for excision (Jacobs and Schar, 2012). The 
resultant AP site is processed by AP endonuclease 1 (APE1), that hydrolyzing the 
phosphodiester backbone 5’ to the AP site, creates a 3’OH and a 5’-deoxyribose phosphate 
moiety (5’-dRP) (Lindahl, 1974). APE1 interacts with DNA polymerase β (polβ), which in 
turn hydrolyzes the 5’-dRP and fills in the single-nucleotide gap. The gap can be sealed by 
the protein complex DNA ligase III / XRCC1 (X-ray repair cross-complementing protein 
1) (Kubota et al., 1996). In this process only the site of the lesion is repaired, is termed 
short-patch BER, and represents 80 – 90 % of all BER in a cell. An alternative 
synthesis/ligation step, called long-patch BER, is initiated when DNA polβ is unable to 
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remove the 5’-dRP and several nucleotides are needed to fill the gap. The resultant 
displaced overhang is cleaved by Flap endonuclease 1 (FEN1) prior to completion by 
another ligase complex (DNA Ligase I) (Frosina et al., 1996). 
 
1.2.2 Mismatch repair 
MMR plays an important role in post-replication repair of misincorporated bases and 
insertion/deletion loops, both of which can result from errors during DNA polymerase 
activity. In mammals there are two different MMR pathways, canonical (classical) MMR 
and non-canonical MMR (ncMMR) (reviewed by (Bak et al., 2014)). 
The MMR pathway can be divided into three steps: 1) recognition, 2) excision of the 
region surrounding the mismatch, and 3) re-synthesis and ligation of the gap. The 
canonical MMR pathway is a high fidelity process involving two major protein complexes, 
hMutS and hMutL. The initial recognition step is carried out by one of two hMutS 
orthologous complexes: MSH2/6 (hMutSα) recognizes mismatches and single-base loops, 
while MSH2/3 (hMutSβ) recognizes larger insertion/deletion loops. The bound proteins 
recruit MLH1/PMS2 (hMutLα) heterodimeric complex that activates exonuclease 1 
(EXO1) - mediated degradation of the damaged DNA strand (Kunkel and Erie, 2005; Tran 
et al., 2004). The gap left by EXO1 is resynthesized by DNA polymerase δ and ε and 
sealed by DNA ligase I (Gu et al., 1998). 
In contrast to replication-linked classical MMR, non-canonical MMR can be highly 
mutagenic and is activated by a variety of lesions (Pena-Diaz et al., 2012). In B cells, 
MMR is recruited during the process of somatic hypermutation (SHM) to generate 
antibody diversity (see section 1.3.1.1) (Cascalho et al., 1998; Rada et al., 2004). 
Following the mismatch recognition by hMutSα and hMutLα, PCNA is recruited and 
monoubiquitinated at lysine 164 (mUb-PCNA) (Langerak et al., 2007). mUb-PCNA allows 
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for the binding of DNA-polymerase η, a translesion polymerase that mediates error-prone 
DNA synthesis, thus leading to the incorporation of mutations (Chahwan et al., 2012). 
 
1.2.3 Further repair pathways  
Aside from BER and MMR, other DNA repair pathways recognize specific DNA lesions, 
such as pyrimidine dimers and DSBs, such as NER, HR, and NHEJ.  
NER can recognize and remove a wide range of helix distorting base lesions, including 
pyrimidine dimers from UV light. NER has two sub-pathways that differ with regards to 
lesion recognition: a) transcription-coupled NER (TC-NER) takes place at DNA damage 
sites blocking transcription, with the stalled polymerase serving for lesion recognition 
(Fousteri and Mullenders, 2008); b) global genome NER (GG-NER) is recruited to sites of 
damage by DNA damage-binding proteins and eliminates lesions throughout the genome 
(Gillet and Scharer, 2006). 
HR together with NHEJ is the main pathway involved in DSBs repair. HR occurs 
specifically in late S and G2 phases of the cell cycle. It is an error-free mechanism as it 
uses the genetic information contained in the undamaged sister chromatid as a template (Li 
and Heyer, 2008). In contrast to HR, NHEJ functions throughout the cell cycle and 
involves the elimination of DSBs by direct re-ligation of the broken ends. Small insertions 
and deletions at the breakage site account for the error prone nature of NHEJ pathway 
(Lieber, 2010). 
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1.3 BALANCE BETWEEN DNA DAMAGE AND DNA REPAIR 
As shown in Table 1, as a result of exposure to various damaging agents, a cell experiences 
up to 105 spontaneous DNA lesions per day. The fine crosstalk among DNA repair 
pathways ensures that the lesions are repaired efficiently. Furthermore, in case of excessive 
damage, the cell can also undergo programmed-cell death to avoid tumorigenic 
transformation and to ensure the survival of the organism. On the other hand, mutations 
themselves are a fundamental process without which evolution could not occur. Mutations 
that arise from inaccurate DNA repair mechanisms, if controlled, can lead to genetic 
variation, thus creating biological novelty that can be positively selected during evolution. 
A fine balance between genome stability and instability allows just enough genetic 
variation for evolution to take place. 
 
1.3.1 Disturbing the balance toward evolution: Activation-induced deaminase 
Activation-induced deaminase (AID) is a natural DNA mutator finely regulated and 
expressed in our body. This enzyme introduces DNA lesions by deaminating cytosine (dC) 
residues to uracils (dU) in single strand DNA (ssDNA) (Figure 2A) (Dickerson et al., 
2003). dUs, upon double strand DNA (dsDNA) reformation can activate various DNA 
repair mechanisms, or if ignored lead to transitions during replication. Given its ability to 
mutate DNA, AID is a key player in the homeostasis between survival and evolution. 
AID is a 24 kilodaltons (kD) protein discovered in 1999 in a subtractive hybridization 
screen, comparing unstimulated and stimulated mouse B cells. It was shown to be 
expressed in activated B cells in the germinal center (GC) (Muramatsu et al., 1999). 
Subsequent studies have highlighted the importance of AID in mediating two processes in 
acquired immunity, somatic hypermutation (SHM) and class switch recombination (CSR); 
both are part of antigen-dependent antibody diversification (Muramatsu et al., 2000). 
Furthermore, in chicken and some ruminants, AID mediates immunoglobulin gene 
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conversion (iGC), the primary mechanism used to generate immunoglobulin (Ig) gene 
diversity (Arakawa et al., 2002; Harris et al., 2002). Initially, AID was thought to be an 
RNA editing enzyme, but it was later on discovered that AID could mutate Escherichia 
coli (E. coli) DNA, providing substantial insight into its mechanism of action (Petersen-
Mahrt et al., 2002). 
 
 
 
Figure 2: AID properties and structure. 
A) The deamination reaction catalyzed by AID on ssDNA produces a uracil from a cytosine, resulting in a 
dU:dG mismatch in dsDNA. B) AID protein structure is depicted in light blue, with the functional domains 
in different colors. The catalytic active site is highlighted in blue, the zinc-coordinating amino acid residues 
in black and the critical sites of phosphorylation in orange. 
 
AID is the founding member of the APOBEC (apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like) family of cytosine deaminases, with the human genome 
comprising 10 members, each playing a potential different physiological function, but 
sharing a common zinc-binding catalytic domain (Conticello et al., 2005). AID is 
  26 
composed of an N-terminal domain containing a nuclear localization signal (NLS), 
essential for SHM (Brar et al., 2004); a catalytic domain where a histidine and two 
cysteines coordinate a zinc atom and form a pocket, with glutamic acid (E) providing the 
proton donor; and a C-terminus with a nuclear export signal (NES), essential for CSR 
(Barreto et al., 2003; Prochnow et al., 2007) (Figure 2B). 
For efficient deamination, AID requires ssDNA, which during Ig diversification can be 
provided by the concomitant transcription elongation process (Basu et al., 2011; Pavri et 
al., 2010; Vaidyanathan et al., 2014; Willmann et al., 2012). Moreover, biochemically AID 
has a preference for dC in the context of WRC (W= dA or dT; R= dA or dG) (Beale et al., 
2004; Morgan et al., 2004; Pham et al., 2003). Aside from its involvement in antibody 
affinity maturation (see section 1.3.1.1), several studies revealed that AID is expressed 
outside of the immune system, such as primordial germ cells (PGC), embryonic stem cells, 
oocytes, and spermatocytes (Morgan et al., 2004; Schreck et al., 2006), and hence can be 
regulated by non-B cell specific factors such as hormones (estrogen, progesterone, and 
androgen) (Lin et al., 2009; Pauklin and Petersen-Mahrt, 2009; Pauklin et al., 2009). This 
suggested additional functions of AID outside the immune system, such as epigenetic 
reprogramming and active demethylation, which is supported by AID’s ability to 
deaminate 5-methylcytosine (Bhutani et al., 2010; Franchini et al., 2014; Franchini et al., 
2012; Morgan et al., 2004; Popp et al., 2010; Rai et al., 2008). 
 
1.3.1.1 AID in SHM and CSR 
In its daily fight against pathogens, the immune system creates a large repertoire of low 
affinity antibodies, and upon antigen encounter produces high affinity antibodies for each 
target. Immunoglobulins are heterodimeric proteins composed of two heavy (H) and two 
light (L) chains linked via disulfide bridges. Each component chain contains one N-
terminal variable (V) domain, which contributes to the antigen-binding site, and one or 
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more C-terminal constant (C) domains that determine the isotype (Schroeder and Cavacini, 
2010). In mammals there are two classes of light chain loci (IgL), termed Igκ and Igλ, and 
a single heavy chain locus (IgH).  
Upon RAG1/2 dependent V(D)J recombination in the bone marrow (Rajewsky, 1996), 
IgM molecules are expressed on the surface of B cells as part of the diverse naïve Ig 
repertoire. B cells expressing fully reactive IgM can colonize secondary lymphoid organs, 
where they undergo a physiological process of alterations of the rearranged Ig locus, 
termed Ig locus diversification, with AID playing a fundamental role. Somatic 
hypermutation introduces point mutations at high rates into variable region exons of IgH 
and IgL genes, which upon antigen selection generates antibodies with higher affinity for 
antigens (Neuberger et al., 2003).  After AID initiates SHM by the deamination of dC, the 
resulting dU:dG mismatch becomes a substrate for different DNA repair pathways 
(Petersen-Mahrt, 2005). If DNA replication takes place before mismatch recognition, a 
transition mutation of dC to dT will occur (Neuberger et al., 2003). If uracil is recognized 
and removed by uracil-DNA glycosylase (UNG), an AP site can become a template for 
DNA replication, leading to the incorporation of any nucleotide and resulting in both 
transitions and transversions (by the action of low fidelity polymerases) (Di Noia and 
Neuberger, 2007; Neuberger et al., 2003). In addition to be partially processed by BER, the 
dU:dG mismatch or the AP site can be recognized by the MMR machinery, which allows 
for mutations at dA:dT near the initiating dU:dG lesion through an error-prone repair 
process (Cascalho et al., 1998; Rada et al., 2004) (see section 1.2.2). 
The IgH is organized in sub-classes (µ, δ, γ, α, ε), with each defining the effector function 
of the antibodies upon class switch recombination (CSR). CSR is a DNA recombination 
event between the initially expressed CH exons (Cµ) and downstream exons, such as Cγ, 
Cα and Cε, with the DNA in between being deleted, leading to the expression of IgG, IgA 
and IgE antibodies (reviewed in (Xu et al., 2012)). Aside from the deamination activity, 
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CSR also requires AID’s C-terminus, a region seemingly unnecessary for deamination and 
SHM (Barreto et al., 2003; Shinkura et al., 2004; Ta et al., 2003). AID deaminates dC 
residues in the switch region of CH. The removal of uracil by either UNG or components of 
ncMMR pathway introduces nicks or gaps on opposite strands of the switch region, 
leading to DSBs formation (Begum et al., 2004; Zan and Casali, 2008).  
It is now clear how mutations, if controlled and programmed, contribute to genetic 
diversity. AID, by introducing mutations in the Ig locus, plays an important role in the 
positive selection and evolution of antibodies, a process required for an optimal immune 
response. On the other hand, uncontrolled expression of AID contributes to aberrant 
genetic changes and cancer. 
 
1.3.2 Disturbing the balance towards cancer  
The alteration of the balance between genomic stability and DNA lesions can cause an 
accumulation of somatic mutations, leading to genome instability, the hallmark of all 
human cancers (Hanahan and Weinberg, 2011). Cancer is an evolutionary process: among 
the cells that continuously acquire genetic variation by mutations and selection, 
occasionally a single cell acquires a set of sufficiently advantageous mutations that confers 
autonomous proliferation and transformation (Stratton et al., 2009). Tumors are 
heterogeneous and are composed of multiple cell types that participate in heterotypic 
interactions with one another. They are characterized by biological capabilities acquired 
during the multistep transformation process, which include: a) sustaining proliferative 
signaling, b) evading growth suppressors, c) resisting cell death, d) enabling replicative 
immortality, e) inducing angiogenesis, f) activating invasion and metastasis, g) avoiding 
immune destruction, h) deregulating cellular metabolism, i) promoting inflammation and, 
as already mentioned above, genome instability and mutations (Hanahan and Weinberg, 
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2011). Importantly even among the individual cell types, cellular heterogeneity derives 
from functional heterogeneity encoded by multiple aberrations in the cancer genome. 
Considering that the spontaneous mutation rate in normal cells is not sufficient to account 
for the number of mutations found in human cancers (Loeb et al., 1974), somatic mutations 
found in cancer genomes are the consequence of exogenous or endogenous exposure to 
mutagens (section 1.1), defective or error-prone DNA repair mechanisms (section 1.2), 
intrinsic infidelity of the DNA replication machinery, and enzymatic modification of the 
DNA (section 1.3.1). As a result of the action/deregulation of the aforementioned 
pathways, cancer cells express the so called mutator phenotype, which allows a 
progressive accumulation of mutations during tumor progression (Loeb et al., 1974). 
Indeed, by the time cancer is detected clinically, cancer cells already contain thousands of 
mutations (Figure 3).  
 
Figure 3: Mutation accumulation during cancer evolution. 
Random mutations occur when DNA damage exceed the cell’s capacity for DNA repair. For a solid tumor, 
more than 20 years pass from the time of exposure to a damaging source to the clinical detection of a tumor. 
This process starts with mutations in genes involved in genome stability (red circle), resulting in enhanced 
mutagenesis. Driver (blue triangle) and passenger (white rectangles) mutations accumulate after each round 
of selection in the tumor microenvironment, leading to cellular heterogeneity.  
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Mutations can be classified according to their consequence for cancer development. Driver 
mutations confer growth advantage on the cell and have been positively selected during 
cancer evolution, while passenger mutations do not confer any selective advantage and do 
not contribute to cancer development (Stratton et al., 2009). Driver mutations usually 
cluster in cancer genes, whereas passenger mutations are more or less randomly distributed 
and represent a rich source of historical information of the cancer genome, also known as 
mutational signature (Alexandrov et al., 2013; Helleday et al., 2014). This signature 
contains the scar of different mutational events that have occurred during the lifetime of 
the tumor and within a tumor, with different signatures as a result of heterogeneous 
processes, increasing the complexity of the final landscape (Alexandrov et al., 2013; Nik-
Zainal et al., 2012). Recently, using next-generation sequencing (NGS), 30 primary human 
tumors have been analyzed and 21 different mutational signatures identified: some 
characterized by prominence of dC>dT substitutions, while others with primarily dC>dG 
transversions (Alexandrov et al., 2013; Nik-Zainal et al., 2012). 
Beyond point mutations, changes in the DNA sequence of cancer genomes include 
genomic rearrangements such as insertions/deletions, chromosomal translocations and 
amplifications, that occur at much lower frequency than single base substitutions do 
(Stratton et al., 2009). 
 
1.3.3 Cancer genes 
In the last four decades, many important genes responsible for tumor progression have 
been discovered. Cancer arises from the accumulation of mutations in three types of so 
called cancer genes: oncogenes, tumor suppressor genes, and genes that maintain genomic 
integrity. 
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Alterations of an oncogene can render the gene constitutively active or active under non-
physiological conditions. One mutate allele is often sufficient to confer growth advantage 
of a cell, with oncogene activation being the result of chromosomal translocation, gene 
amplification, or point mutations in residues critical for its activity (gain of function 
mutation). Key transforming oncogenes include RAS, MYC and BRAF, which under 
normal conditions govern the processes of growth, proliferation, and survival (Hanahan 
and Weinberg, 2011).  
For oncogenesis, tumor suppressor genes are targeted in the opposite way and mutations 
impair the activity of the gene product. Here, changes arise from: missense mutations at 
essential residues for the activity, truncations to inactivate the protein, insertions or 
deletions in the gene, or epigenetic silencing of the expression (Vogelstein and Kinzler, 
2004). Inactivation of both alleles is generally required to confer a selective advantage to 
the cell, known as the two-hit hypothesis (Knudson, 1971). During this process, a cell with 
a single inactive allele (either somatically acquired or genetically inherited) receives a 
second hit in its remaining functional copy of the tumor suppressor gene, thus acquiring a 
homozygous loss genotype – also known as loss of heterozygosity (LOH) (Knudson, 
1971). In their physiological context, tumor suppressor genes operate in various ways to 
limit cell growth and proliferation, such as by promoting apoptosis or by blocking the cell 
cycle (Weinberg, 1995). Two of the most studied tumor suppressor genes are TP53 and 
APC (see section 1.3.3.1). 
The third class of cancer genes, called genome stability genes, promotes tumorigenesis 
when mutations occur in MMR, NER, BER and HR genes, or in critical DNA replication 
checkpoint genes (Cleaver, 2005; Friedberg, 2003; Helleday, 2010; Peltomaki, 1997). 
Stability genes keep genetic alterations at minimum, and thus their inactivation lead to the 
mutator phenotype (Loeb et al., 1974; Peltomaki, 2003). Similar to tumor suppressor 
genes, usually both alleles of stability genes are inactivated during cancer progression. 
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Mutations in cancer genes can occur both in the germline, resulting in hereditary 
predisposition to cancer, or in somatic cells leading to sporadic tumorigenesis. The Cancer 
Gene Census, a database of genes mutated in human cancers, contains 522 genes (Forbes 
et al., 2015). Of these, ~ 90 % are altered by somatic mutations and ~ 20 % by germline 
mutations. Moreover, approximately 90 % of somatic mutated genes are acting in a 
dominant manner, while 10 % act in a recessive manner (Stratton et al., 2009). 
 
1.3.3.1 Tumor suppressors TP53 and APC 
The tumor suppressor TP53, known also as “guardian of the genome”, is a transcription 
factor essential for preventing inappropriate cell proliferation and maintaining genome 
integrity after genotoxic stress (Lane, 1992). TP53 mutations are the most common genetic 
alterations found in human cancer, ranging from 5 % to 80 % depending on the type, stage, 
and etiology of the tumor (Petitjean et al., 2007a). Germline mutations are associated with 
Li-Fraumeni syndrome, a disorder that greatly increases the risk of developing cancer via 
LOH (Li et al., 1988; Nichols et al., 2001). TP53 responds to oncogene activation, 
hypoxia, loss of normal cell contacts, and telomere shortening, each of which can lead to 
TP53-dependent transcriptional regulation of hundreds of genes. The three main 
consequences of TP53 activation are cell cycle arrest, senescence, and apoptosis. Aside 
from these outputs, other TP53 activities impacting tumor suppression include autophagy, 
regulation of metabolism, and angiogenesis (Sablina et al., 2005; Teodoro et al., 2007; 
Vousden and Ryan, 2009). Importantly, the choice between these responses is influenced 
by the type of cell, type of stress, and the action of TP53 co-activators. For example, in 
response to DNA damage, some cell types undergo TP53 mediated apoptosis (e.g. T 
lymphocytes) (Strasser et al., 1994), whereas others undergo senescence (e.g. mouse 
embryonic fibroblasts, MEFs).  
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Figure 4: TP53 protein structure. 
The TP53 protein consists of 393 amino acids. The functional domains are depicted in different colors. The 
N-terminal domain contains the transactivation domain and the poly-proline domain (PXXP) is important for 
the interaction with MDM2. The central region includes the DNA binding domain, necessary for sequence-
specific DNA targeting. The C-terminal domain contains a nuclear localization signal (NLS), an 
oligomerization domain, a nuclear export signal (NES), and a regulatory domain. 
  
The TP53 gene contains 11 exons and encodes for a 393 amino acids containing protein 
(53 kD), whose structure is depicted in Figure 4. TP53 protein is composed of several 
structural and functional domains: an amino-terminal domain (residues 1 – 42), a proline-
rich region with repetitive PXXP sequences (residue 63 – 97 where X is any amino acid), a 
highly conserved central core domain (residues 98 – 292), and a carboxyl-terminal region 
containing an oligomerization domain (residues 324 – 355), a regulatory domain (residues 
363 – 393), a nuclear localization signal, and three nuclear export signals sequence. The N-
terminal domain is required for transactivation activity and interaction with various factors 
including its regulator MDM2 (murine double mutant 2) (Fields and Jang, 1990; Lin et al., 
1994). The poly-proline region is important for inducing cell death, but not growth arrest 
(Sakamuro et al., 1997), while the central core is composed mainly of the DNA binding 
domain (DBD), required for sequence-specific DNA binding (Kern et al., 1991). The vast 
majority (80 %) of TP53 mutations found in human cancers are located in the DNA 
binding domain (Petitjean et al., 2007b). The oligomerization domain downstream of the 
nuclear localization domain is necessary for the tetramerization of TP53, enhancing DNA 
binding (McLure and Lee, 1998). Finally, the C-terminal tail is composed of a regulatory 
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domain essential for transactivation and binding (Kim et al., 2012), that undergoes PTMs, 
including phosphorylation and acetylation (reviewed in (Meek and Anderson, 2009)). 
TP53 is conserved across species, with the highest homology found in the DBD. Many 
animal models, including knock-in and knockout mice, have been developed to study TP53 
function and its implication in tumorigenesis (reviewed in (Lozano, 2010)). For example, 
mice lacking trp53 (p53) are viable and prone to spontaneous tumor development by 6 
months of age, mainly sarcomas and lymphomas (Donehower et al., 1992). Similarly, three 
p53 zebrafish models (tp53I166T and tp53N168K in exon 6, tp53M214K in exon 7) generated via 
target-selected mutagenesis strategy, lack apoptosis and cell-cycle arrest responses to DNA 
damage. After 8.5 months of age, these animals spontaneously develop malignant 
peripheral nerve sheath tumors (MPNSTs) with an incidence of 25 % (Berghmans et al., 
2005) and sarcomas with an incidence of 50 % (Parant et al., 2010). 
 
APC (Adenomatous Poliposis Coli) is a tumor suppressor gene found mutated in the 
majority of sporadic colorectal cancers (80 %) (Cottrell et al., 1992; Miyoshi et al., 1992). 
Germline mutations are responsible for familial adenomatous polyposis (FAP) syndrome, 
characterized by the development of many colonic polyps early in the adulthood that can 
systematically evolve into malignant tumors (Bodmer et al., 1987; Kinzler et al., 1991; 
Nakamura et al., 1991). Unlike TP53, mutations in APC, both germline and somatic 
mutations, predominantly result in protein truncations (Cottrell et al., 1992; Miyoshi et al., 
1992; Nagase and Nakamura, 1993). 
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Figure 5: Functional domains of APC protein. 
APC full-length protein consists of 2843 amino acids and includes several domains, indicated here with 
different colors. For details see text. 
 
The APC gene spans 107 kilobases (kb) and contains 21 exons. Many transcript variants 
are present due to alternative splicing, with the most common isoform consisting of 2843 
amino acids encoded by exons 2 – 16 (Horii et al., 1993). Exon 16 includes more than 75 
% of the coding sequence of APC and is the most frequently targeted exon for cancer 
mutations (containing the Mutation Cluster Region - MCR). The APC protein consists of 
numerous domains that allow its interaction with a variety of cytoplasmic proteins (Figure 
5). The N-terminus is composed of an oligomerization domain, important for 
homodimerization (Su et al., 1993), and an armadillo region that allows the binding to its 
partners. The central region is made of multiple 15- or 20-amino acid repeats required for 
binding of β-catenin and contains the MCR (Rubinfeld et al., 1993). The C-terminus 
contains a basic domain and binding sites for two different proteins (EB1 and HDLG) 
(Fearnhead et al., 2001). APC is a crucial component of the β-catenin destruction complex 
that catalyzes the phosphorylation of β-catenin (Munemitsu et al., 1995). Moreover, APC 
has a broad spectrum of functions, including control of the WNT signal transduction 
pathway, cell adhesion and migration, apoptosis, and chromosomal segregation during 
mitosis (Fearnhead et al., 2001). 
Mice carrying a homozygous deletion of Apc are embryonic lethal (Moser et al., 1995), but 
a number of mouse models have been created that mimic the human pathology, with the 
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development of multiple intestinal polyps (reviewed in (McCart et al., 2008)); e.g. N-ethyl-
N-nitrosourea (ENU) induced Multiple intestinal neoplasia (Min) mouse, which carries a 
point mutation at codon 850 (Moser et al., 1990). 
 
1.3.4 AID and cancer 
As discussed in section 1.3.1.1, AID is the key protein for antibody diversification. A 
number of mechanisms are responsible for confining AID activity to the Ig locus in B 
cells, such as target specificity controlled by the interaction with several proteins (Pavri et 
al., 2010; Sayegh et al., 2003; Willmann et al., 2012), subcellular localization (Hu et al., 
2013; Maeda et al., 2010), post-transcriptional regulation (de Yebenes et al., 2008; Teng et 
al., 2008; Tran et al., 2010), and PTMs (Basu et al., 2009). In addition to Ig genes, AID is 
able to target non-Ig genes in B cells, including oncogenes such as MYC, PAX5, BCL-6 
and PIM1 (Pasqualucci et al., 1998; Pasqualucci et al., 2001; Shen et al., 1998; Wang et 
al., 2004). These genes normally escape acquisition of mutations due to the combined 
action of MMR and BER. However, in response to cellular stress including viral infection 
(Epeldegui et al., 2007; He et al., 2003), the actions of DNA repair mechanisms can be 
altered, leading to the accumulation of AID-dependent mutations and possible tumor 
induction/progression (Liu et al., 2008). 
B cell malignancies can bear chromosomal translocations involving Ig switch regions and 
oncogenes as a result of aberrant CSR. In particular, in Burkitt’s lymphoma, AID drives 
the chromosomal translocation between IgH and C-MYC (Ramiro et al., 2004; Robbiani et 
al., 2008). Furthermore, AID is expressed at different levels in all phenotypic subtypes of 
diffuse large B-cell lymphomas (DLBCL) (Pasqualucci et al., 2004). 
Aside from B cell malignancies, AID can be genotoxic in other tissues, since it can be 
induced by pro-inflammatory cytokines (Endo et al., 2007; Endo et al., 2008; Komori et 
al., 2008), microbial infections (Kim et al., 2013; Matsumoto et al., 2007), and hormones 
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(Lin et al., 2009; Pauklin and Petersen-Mahrt, 2009; Pauklin et al., 2009). Inflammation of 
the colon (known as inflammatory Bowel disease) induces aberrant AID expression via 
NF-kB, frequently leading to colitis-associated cancer (Takai et al., 2012), while 
Helicobacter pilori infection triggers AID up regulation resulting in mutations in TP53 and 
gastric cancer progression (Matsumoto et al., 2007; Shimizu et al., 2014). Furthermore, 
activation of AID by androgens in prostate cancer lead to chromosomal translocation (Lin 
et al., 2009), pointing the potential link between hormone exposure and AID/APOBEC 
mediated oncogenesis. 
Initial bioinformatics analysis uncovered that dC to dT transitions occurring in TP53 and 
APC tumor suppressor genes are embedded within DNA deaminases footprints (Beale et 
al., 2004; Morgan et al., 2004). The role of DNA deaminases as mutators in oncogenesis 
was supported by uncovering TP53 mutations in AID footprints after H. pilori infection 
(Shimizu et al., 2014), and TP53 mutations from breast cancer samples showing 
characteristic AID/APOBEC Ig-like mutation signature (Lindley, 2013). More recently, 
NGS approaches of human cancers have provided further support for AID and other DNA 
deaminases involvement in the generation of oncogenic mutations. First, C>T DNA 
deaminase mutational signature was identified in breast cancer sequence data (Burns et al., 
2013a; Nik-Zainal et al., 2012), then it was extended to different type of tumors, where 
AID/APOBEC mutagenic activity was linked to clusters of unstable genomic regions 
called kataegis (Alexandrov et al., 2013; Burns et al., 2013b; Roberts et al., 2013; Zhang et 
al., 2015).  
 
1.3.5 Animal models of cancer 
Animal models have been instrumental in the study of genes involved in human cancer 
initiation and progression. Both spontaneous and carcinogen-induced malignancies have 
been studied in different species, from worms to drosophila, to zebrafish, to mouse and 
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dog. For over a century rodents and especially mice are the model of choice for several 
reasons: we share 95 % of the same genes and pathways; mice are inbreed, easy to be 
genetically manipulated, cheap to maintain, small in size, and they reproduce quickly 
(Cheon and Orsulic, 2011).  
Although initially used as a classical developmental and embryological model, the 
identification of thousands of zebrafish mutants through genetic screens in the 1990s 
established zebrafish as a model for human diseases, including cancer. Despite the obvious 
differences in the physiology of fish and humans that can alter the phenotypic outcome of 
the disease in this model, zebrafish has a number of advantages over the use of mice: 1) the 
large number of offspring, 2) transparent embryos, 3) small size, 4) ease of daily upkeep, 
and 5) fertilization ex utero that allows easy genetic manipulation and continuous analysis 
of the developing embryo (Lieschke and Currie, 2007).  
Animal models of cancer are very heterogeneous and include four main classes: 1) 
xenograft models with established human/mouse tumor cell lines; 2) primary tumorgraft 
models; 3) germline transgenic and conditional transgenic models (GEMs); and 4) 
carcinogen-induced models (reviewed in (Cheon and Orsulic, 2011; Ruggeri et al., 2014)). 
In the first class, tumor derived cell lines or tissue pieces are implanted into syngeneic or 
immune-compromised mice allowing a reproducible evaluation of pharmacological 
screening. The main disadvantages are the weak histological and phenotypic similarities to 
the primary tumor, loss of heterogeneity, low metastatic rates, and loss of the primary 
tumor microenvironment.  The model can be improved, if the tumor cells are implanted 
into the organ of origin (orthotopic models), hence the correct microenvironment is 
established and a higher metastatic rate is observed (Cheon and Orsulic, 2011; Ruggeri et 
al., 2014). 
Primary tumorgraft models, also referred to as avatar, involve the direct implantation of 
fresh tumor biopsies into immune-deficient mice, preserving genotypic and phenotypic 
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features of the original tumor (Kopetz et al., 2012). Weaknesses of this model are the 
limited engraftment rates, long latency for tumor development, high front-end costs, and 
reduced accessibility to fresh tumor samples (Ruggeri et al., 2014). In contrast to mouse, 
transplantation of human cancer cells into zebrafish embryos or irradiated transparent 
zebrafish (Casper fish (White et al., 2008)) allows to follow cancer progression in real-
time. Importantly, this model also provides a means to monitor drug response of patient-
derived biopsy in a cost-effective and time-efficient manner (Jung et al., 2012; Lee et al., 
2005; Veinotte et al., 2014). 
The third class includes animals in which a tumor suppressor gene or oncogene is 
expressed/inhibited ubiquitously or in a tissue-temporal specific manner, thus 
recapitulating how an important mutation induces oncogenesis. This can help in 
elucidating deregulated molecular mechanisms linked to the gene itself. Despite the 
genetic and histologic similarities to human cancers, the main limitations are a low and 
heterogeneous penetrance, heterogeneous genetic background, as well as other technical 
difficulties such as targeting of mouse embryonic stem (ES) cells by homologous 
recombination (Thomas and Capecchi, 1987), the generation of a germline transmitted 
chimera, and subsequent complex breeding (Cheon and Orsulic, 2011; Politi and Pao, 
2011; Ruggeri et al., 2014). Transgenic zebrafish lines expressing human oncogenes 
ubiquitously or in a tissue-temporal specific manner have been generated using the 
Gal4/UAS systems (Scheer and Campos-Ortega, 1999) and the Tol2 mediated approach 
(Kawakami, 2007; Urasaki et al., 2006), with the advantage of following cancer 
progression in live animals. New genome editing techniques using engineered nucleases 
(see section 1.4), such as zinc-finger nuclease (ZFNs), transcription activator-like effector 
(TALEN) nuclease, and clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated (Cas) system, provide us with alternative methods of 
generating GEMs, accelerating the generation time (Reviewed in (Gaj et al., 2013)). 
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Carcinogen-induced models recapitulate multistep tumor progression in response to 
environmental DNA damaging agents (tobacco smoke associated carcinogens) and tumor-
promoting agents, such as and N-ethyl-N-nitrosourea (ENU). The phenotypic outcome is 
very similar to certain human cancers, and allows one to also investigate the contribution 
of inflammatory processes in tumor development (Cheon and Orsulic, 2011; Ruggeri et al., 
2014). However, this approach has several limitations, such as the inability to make 
specific targeted mutations, prolonged time frames, and costs required for dose 
administration. In zebrafish, chemical mutagens (ENU), psoralen and radiation can be used 
to create stable mutant lines with knock down gene function, with the limitation of random 
mutations being inserted (Wienholds et al., 2003). 
 
1.4 NOVEL APPROACHES FOR GENOME EDITING 
New technologies have emerged that enable targeted editing of genomes in diverse 
systems. These approaches include the generation of different modular proteins in which 
the DNA binding domain is fused to an effector domain to alter genomic structure and 
function. The DNA recognition domain can be customized to recognize virtually any 
sequence and is typically based on the structure of natural DNA binding proteins, such as 
zinc finger proteins (ZFP) and transcription activator-like effectors (TALE). The 
combination of the DNA-binding protein with effector domains create functional enzymes 
including nucleases (Christian et al., 2010; Kim et al., 1996), transcription factors (Beerli 
et al., 1998; Zhang et al., 2011), and methyltransferases (Meister et al., 2010).  
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1.4.1 Zinc finger proteins 
The Cys2-His2 zinc finger domain is among the most common DNA binding motif found in 
eukaryotes and consists of 30 amino acids in a ββα conformation, where the α-helix 
projects into the major groove of the DNA and recognizes 3 – 4 adjacent nucleotides 
(Pavletich and Pabo, 1991). This modular structure of ZFP has been extensively 
engineered through site-specific mutagenesis and the generation of large combinatorial 
libraries to create a unique zinc finger domain with specificity for all 64 possible 
trinucleotide combinations (Pabo et al., 2001). In addition, these preselected modules can 
be linked together in tandem to target DNA sequences of 9 – 18 nucleotides. For many 
years, ZFP technology has been the only approach available to create custom DNA binding 
proteins and enzymes (Kim et al., 2009; Mandell and Barbas, 2006). However, engineering 
ZFPs with high activity and specificity remains technically challenging, and requires high-
throughput selection of large libraries to find the functional protein. This is predominantly 
due to difficulty in understanding the prediction of ZFP DNA-binding specificity and 
affinity (Maeder et al., 2008). 
 
1.4.2 Transcription activator-like effectors 
In 2009, the discovery of the modular DNA recognition code by TALE proteins (Boch et 
al., 2009; Moscou and Bogdanove, 2009) has led to the expansion of an alternative option 
for customable engineered DNA binding proteins. TALEs are naturally occurring DNA-
binding proteins produced by plant pathogenic bacteria to regulate host gene expression. 
They bind effector-specific DNA sequences and transcriptionally activate the expression of 
genes that may contribute to bacterial colonization (Kay et al., 2007; Romer et al., 2007). 
TALEs contain N- and C-termini important for localization and activation respectively, 
and a central region for DNA recognition. The central domain comprises as many as 30 
tandem repeats of a 33- to 35-amino acids sequence motif. This sequence is largely 
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conserved, with the exception of two adjacent amino acids at position 12 and 13, termed 
repeat variable diresidue (RVD), and it determines the nucleotide binding specificity of 
each TALE. Repeats with different RVDs recognize different DNA base pairs (bp) with 
one-to-one correspondence, constituting a straightforward cipher repeat, called TALE 
DNA binding code (Boch et al., 2009; Meckler et al., 2013; Moscou and Bogdanove, 
2009). Importantly, each repeat consists of two α helices connected by a three-residue loop 
that contains the RVDs (RVD loop). Sequential repeats bind to one DNA strand with 5’ to 
3’ directionality. Because of their modularity, TALE proteins have become an attractive 
tool for genome editing, with many protocols available for an easy and rapid assembly of 
custom engineered binding proteins. 
 
1.4.3 Clustered regularly interspaced short palindromic repeat-Cas system 
Distinct from the site-specific targeting tool described above, the CRISPR-Cas system is a 
naturally occurring, adaptive microbial immune system for defense against foreign nucleic 
acids, such as phages and plasmids (Barrangou et al., 2007; Marraffini and Sontheimer, 
2010). CRISPRs were initially found in the E. coli genome in 1987 (Ishino et al., 1987), 
and this family of DNA repeats is present in 90 % of archaeal and 40 % of bacterial 
genomes, with common evolutionary origin (Jansen et al., 2002; Sorek et al., 2008). The 
CRISPR loci are surrounded by the Cas genes, which encode a heterogeneous family of 
proteins with functional domains typical of nucleases, helicases, polymerases and 
polynucleotide-binding proteins (Haft et al., 2005; Jansen et al., 2002). When the CRISPR 
array is transcribed and processed into short CRISPR RNAs (crRNAs), the Cas proteins 
are able to utilize the crRNA molecules to target and destroy the foreign DNA (Garneau et 
al., 2010). In particular, type II CRISPR system recognizes and cleaves the target DNA via 
the RNA-guided endonuclease Cas9, that consists of two noncoding RNAs, the crRNA and 
the trans-activating crRNA (tracrRNA) (reviewed in (Makarova et al., 2015)). Here, each 
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crRNA hybridizes with the tracrRNA forming a complex with the Cas9 nuclease. The 
protospacer-encoded portion of the crRNA guides Cas9 to cleave complementary target-
DNA sequences if adjacent to a short sequence - the protospacer adjacent motif (PAM). 
Cas9 protein includes two nuclease domains, a RuvC-like nuclease domain located at the 
N-terminus and a HNH-like nuclease domain located in the central region (Sapranauskas et 
al., 2011). Recently, the type II CRISPR system was programmed to cut various DNA sites 
in vitro (Jinek et al., 2012), and subsequently it was adapted for facilitating genome editing 
in eukaryotic cells and organisms (DiCarlo et al., 2013; Hwang et al., 2013; Mali et al., 
2013).  
 
1.4.4 Genome editing with site-specific nucleases 
Historically, targeted gene inactivation, replacement or addition have been achieved by 
homologous recombination (Thomas and Capecchi, 1987). However, the low efficiency of 
recombination in model organisms, the technical difficulties as well as the high costs limit 
the use of this approach. With the discovery and the development of synthetic DNA 
binding proteins and the CRISPR/Cas9 system, new efficient and less expensive 
approaches emerged, and became the methods of choice for genome editing (Figure 6). 
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Figure 6: Mechanisms of ZFN, TALEN and CRISPR/Cas9 systems. 
ZFN, TALEN and CRISPR/Cas9 systems induce DSBs with high precision and affinity in the targeted 
genomic sequence. DSB can be repaired by NHEJ pathway resulting in gene disruption, or by HR if the 
donor template is provided, leading to gene correction or replacement. 
 
DNA binding proteins, such as ZFP and TALE, can be fused to the catalytic domain of a 
restriction endonuclease to generate respectively zinc finger nucleases (ZFN) (Kim et al., 
1996) and TALE nucleases (TALENs) (Cermak et al., 2011; Christian et al., 2010; Li et 
al., 2011) that create DSB at the targeted locus. The endonuclease Fok I - modified to 
increase its specificity and activity - acting as a dimer on two target sites, is the nuclease of 
choice. These DSB are usually resolved by NHEJ-mediated repair. Occasionally NHEJ 
introduces small insertions or deletions, resulting in the knockout of the gene function via 
frameshift mutations. Both ZFN and TALENs have been widely used for precise genome 
editing in diverse organisms, including plants (Christian et al., 2010), fish (Huang et al., 
2011), frogs (Lei et al., 2012), flies (Liu et al., 2012), mice (Sung et al., 2013), as well as 
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critical mammalian cells, e.g. human ES cells and induced pluripotent stem (iPS) cells 
(Hockemeyer et al., 2009; Hockemeyer et al., 2011; Lombardo et al., 2007).    
In contrast to ZFN and TALEN methods, which use protein-DNA interactions, Cas9 is 
RNA-guided and uses the base-pairs rules between the engineered RNA and the target 
DNA site. CRISPR/Cas9 requires two components to be introduced and expressed in the 
same cells: the Cas9 nuclease and a guide RNA (gRNA), consisting of crRNA fused to a 
fixed tracrRNA. Two nuclease domains of the Cas9 cut both DNA strands, generating 
DSBs, which are processed by NHEJ mechanisms as described for ZFN and TALENs. 
New advances in the Cas9 system were made, with the creation of a mutant form, known 
as Cas9D10A, harboring only nickase activity (Cong et al., 2013). On the other hand, the 
double mutant of Cas9, D10A and H840A (dCas9), was catalytically dead, creating a 
sequence specific DNA binding protein without any nuclease activity (Jinek et al., 2012). 
The simplicity of the CRISPR/Cas9 system led to the creation of large gRNA libraries 
using array-based oligonucleotide synthesis, engineered to target almost every gene in the 
cell or organism of choice, without the need of creating novel binding proteins (Chen et al., 
2015; Wang et al., 2014). 
 
1.4.5 Regulation of gene expression 
Gene regulation in bacteria and yeast is driven by sequence specific DNA binding proteins. 
In mammals this specificity is lost and replaced with a pleiotropic set of complexes and 
molecular machineries. In the past, researchers have adapted the prokaryotic (e.g. lacO and 
Tet) and yeast (e.g. Gal4) regulatory system to study gene expression in eukaryotes. For 
example, the Tetracyclin-regulated (Tet) system is based on a chimeric transcription factor 
consisting of the bacterial Tet repressor (TetR) fused to an eukaryotic transcriptional 
regulatory domain, which activates (tTA) or silences (tTS) expression from a Tet-
dependent promoter. The Tet-dependent promoter contains several TetR binding sites 
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(tetO), placed upstream of the transcription initiation site and the binding to TetO is 
regulated by tetracycline and its derivative (Berens and Hillen, 2003). The Tet systems 
have been used in vivo for the inducible expression of several transgenes, encoding for 
example reporter genes and oncogenes (Furth et al., 1994). 
The yeast Gal4 system consists in the transcription regulator protein Gal4 that binds 
specifically to UAS (Upstream Activation Sequence) to activate transcription of target 
genes. This tool was widely used in fruit flies (Duffy, 2002), zebrafish (Scheer and 
Campos-Ortega, 1999) and mouse (Ornitz et al., 1991) to study gene functions in vivo. 
Two transgenic lines are needed, one expressing the Gal4 protein under a specific 
promoter, and the other carrying the UAS upstream of the gene of interest. To achieve a 
stronger induction of expression, the Gal4 protein was fused to transcriptional activation 
domains such as herpes simplex VP16 transactivation domain (VP16) (Koster and Fraser, 
2001). Although these natural transcription factors continue to be used in specific 
applications, they are being replaced by the programmable DNA binding proteins ZFP, 
TALE and CRISPR/Cas9, that can be used to control gene regulation at targeted promoter 
or enhancer elements in eukaryotic systems (Beerli et al., 1998; Qi et al., 2013; Tan et al., 
2003; Zhang et al., 2011) (Figure 7). 
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Figure 7: Gene regulation using ZFP-TF, TALE-TF and dCas9-TF. 
ZFP, TALE DNA binding domains, and dCas9 can be fused to transcription activator (VP64) or repressor 
(KRAB) domains and targeted to promoter regions to control gene regulation. The effector domain is 
depicted in yellow, while the green circle represents activation and red circle indicates repression of 
transcription. 
 
For transcriptional activation, ZFP were fused to VP16 or its derivative, VP64 (Beerli et 
al., 1998), while TALEs had their endogenous NLS and acidic transcription activation 
domain replaced with a mammalian SV-40 NLS and VP64 (Zhang et al., 2011), or with the 
mammalian activator domains NF-kB (Maeder et al., 2013b). To achieve transcriptional 
repression, ZFP or TALEs were fused to the Krüppel-Associated Box (KRAB), ERF 
Repressor Domain (ERD), or mSIN3 Interaction Domain (SID) (Beerli et al., 1998; Cong 
et al., 2012; Mahfouz et al., 2012). In addition, TALE proteins can induce transcriptional 
repressors at their target site through steric hindrance of key transcriptional initiation 
elements (Li et al., 2015). 
Because of its large size (190kD), the use of the dCas9 allowed for gene repression by 
sterically blocking RNA polymerase binding or elongation, both in bacteria and 
mammalian cells (Bikard et al., 2013; Qi et al., 2013). Alternatively, dCas9 can be fused to 
transcriptional activator (VP64) (Maeder et al., 2013a) or repressor domains (KRAB) 
(Gilbert et al., 2013), as already described for ZF and TALEs. 
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1.5 AIM 
In somatic cells, DNA damage can be introduced both by endogenous and exogenous 
agents, leading to mutations and DNA recombination. The progressive accumulation of 
DNA lesions in a cell can generate genetic variation by natural selection, or can confer 
autonomous proliferation eventually leading to oncogenic transformation. AID, through its 
mutator activity, is functioning at the balance between DNA stability and instability. 
Mutations introduced at the Ig locus confer positive selection for antibodies, while 
mutations introduced at non-Ig genes contributes to aberrant genetic changes and cancer. 
Although animal models have contributed significantly to the understanding of 
oncogenesis, tumor development is more rapid and homogeneous in animal models as 
compared to the heterogeneity and slow progressive accumulation of mutations during 
human tumor progression. For these reasons, innovative models are needed to better 
understand mechanisms of cancer development. 
The aim of my PhD thesis was to create a new model of neoplasia by inducing low-
frequency mutagenesis in tumor suppressor gene loci over time, to mimic human cancer 
progression. 
To this end, I used the natural DNA damaging protein AID as a tool to induce continuously 
mutations in p53 and Apc tumor suppressor genes, both in cell lines and in laboratory 
animals (zebrafish and mouse). I used different approaches to target AID to the desired 
genomic locus, including TALE and Gal4 DNA binding proteins. TALE-AID fusion 
proteins were used to mutate at low frequency the endogenous p53 locus of mammalian 
cell lines (NIH3T3 and MEFs) and zebrafish, while Gal4-Aid was expressed in mice to 
target p53 and Apc genes (Gal4-Aid/p53UAS/+ and Gal4-Aid/ApcUAS/+). 
The working hypothesis is that by targeting AID to the genomic loci of tumor suppressors 
during the lifetime of an organism, the majority of the mutations will be repaired by the 
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DNA repair machinery, but some will escape these mechanisms, thus accumulating at the 
locus, leading to gene inactivation and cellular transformation.  
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CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 BUFFERS AND REAGENTS 
Items with “*” were prepared by IFOM Kitchen, while items with “**” were prepared by 
IFOM Zebrafish Unit. 
 
CALBIOCHEM® EDTA-free protease inhibitors * 
Denaturing solution*: 1.5 M NaCl, 0.5 M NaOH. 
Danieau solution**: 50 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 
mM HEPES, pH 7.5. 
E3 water**: 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 10-5 % 
Methylene Blue (Sigma). 
FACS buffer: PBS 1X + 2 % Fetal Bovine Serum South Americans (FBS SA, BioWest). 
FACS buffer II: DMEM, 2 % FBS SA, 100 Units/mL penicillin (Microtech®) and 100 
Units/mL streptomycin (Microtech®). 
Hypotonic lysis buffer: 150 mM NH4Cl, 10 mM KHCO3, 100 µM EDTA in dH2O (pH 
7.3). 
I.E.D: Ion-Exchange Decal Unit (Biocare Medical). 
Laemmi buffer 5x: 10 % SDS, 50 % glycerol, 0.1 % bromophenol blue, 50 mM DTT, 150 
mM Tris-HCl pH 6.8. 
Lysis buffer: 0.1 M Tris-HCl pH 8.0, 0.5 mM EDTA, 200 mM NaCl. Freshly added 0.2 % 
SDS and 0.1 mg/mL of proteinase K (Promega). 
MESAB** 1X: 0.4 % Tricaine (3-amino benzoic acid ethyl ester; Sigma), 1 % 
Na2HPO4x2H2O. 
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MOPS 10X: 400 mM Morpholinopropanesulfonic acid (free acid), 100 mM Na-acetate-
3H2O, 10 mM EDTA, adjusts to pH 7.2. 
PBS* 1X: 10 mM phosphate, 137 mM NaCl, and 2.7 mM KCl pH 7.0. 
RIPA-02: 0.1 % NP40, 0.2 % DOC, 200 mM NaCl, 50 mM KCl, 10 mM Tris-HCl pH7.4, 
0.5 mM EDTA, 5 mM β-Mercaptoethanol, freshly added 1X EDTA-free protease 
inhibitors. 
Running Buffer*: 2.5 mM Tris-HCl p.H 8.6, 190 mM glycine, 0.1 % SDS. 
Sorting buffer: PBS 1X, 33 % FBS SA, 300 Units/mL penicillin (Microtech®) and 300 
Units/mL streptomycin (Microtech®). 
Sorting buffer II: DMEM, 33 % FBS, 300 Units/mL penicillin (Microtech®) and 300 
Units/mL streptomycin (Microtech®), 0.3 % gentamicin (50 mg/mL Life Tehcnologies). 
TBE* 1X: 89 mM Tris-HCl pH8, 89 mM boric acid, 2 mM EDTA. 
TBS* 1X: 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
TBST 1X: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween 20. 
TE* 1X: 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA. 
Washing buffer: 0.1X SSC, 0.1 % SDS.  
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2.2 OLIGONUCLEOTIDES 
Table 2: Oligonucleotides used in this thesis. 
Name Sequence 5’ to 3’ Length Orientation Restriction site Application 
SPM431 CTAGTGACTACAAGGACCACGATGGCGACTACAAGG 36 For Spe I EcoRI 
generation of 3X 
flag 
SPM432 ATCACGACATCGATTACAAGGACGATGACGACAAGG 37 For Spe I EcoRI 
generation of 3X 
flag 
SPM433 AATTCACTTGTCGTCATCGTCCTTGTAATCGATGTCG 37 Rev Spe I EcoRI 
generation of 3X 
flag 
SPM434 TGATCCTTGTAGTCGCCATCGTGGTCCTTGTAGTCA 36 Rev Spe I EcoRI 
generation of 3X 
flag 
DMF1828 AGTGCGACATCATCATCGG 19 For - Gal4-Aid amplification 
DMF1829 TCTCTCCTCTTTCACCACG 19 Rev - Gal4-Aid amplification 
SP3018 TCCACCACCCTGTTGCTGTA 20 Rev - Mouse Gapdh mRNA 
SP3033 GCACAGTCAAGGCCGAGAAT 20 For - Mouse Gapdh mRNA 
SP3034 GCCTTCTCCATGGTGGTGAA 20 Rev - Mouse Gapdh mRNA 
LS6917 AGCATGTGTGTCAGAGGTCAG 21 For Kpn I p53 5‘arm (pLS7070) 
LS6920 CACGTCGACCCTTAAGCAATCCTGCCTCA 29 Rev Sal I 
p53 5‘arm 
(pLS7070) (p53 
Br) 
LS6921 CCTACTAGTCAGCCTGAGCATGGAAGTAAG 30 For Spe I 
p53 3‘arm 
(pLS7070) 
LS6924 CTATGCGGCCGCAGGCCCCACTTTCTTGAC 30 Rev Not I 
p53 3‘arm 
(pLS7070) 
LS6932 GTTGGGTGTCTGTAAATCCTG 21 For - Mouse p53 gDNA (Bf) 
LS6934 GAGGTGATGGCTGTGGATG 19 Rev - Mouse p53 gDNA (Ar) 
LS6945 CTTGTGCTGGTCCTTTTCTTG 21 For - Mouse p53 gDNA (Ef) 
LS6946 CAGGTTGCCAGGTCTTTTTC 20 For - p53 32P  3’ probe 
LS6951 CCTTGGGTTACTTTTTCTTGC 20 Rev - p53 
32P 3’ probe 
(p53 Er) 
LS6988 
TCGACGTCGGAGGACTGTCCTC
CGAAGCGGAGGACTGTCCTCCG
ACTTCGGAGGACTGTCCTCCGA
TAC 
69 For Sal I 
UAS sequence  
(pLS7070 and 
pLS7106) 
LS6989 
TCGAGTATCGGAGGACAGTCCT
CCGAAGTCGGAGGACAGTCCTC
CGCTTCGGAGGACAGTCCTCCG
ACG 
69 Rev Xho I 
UAS sequence  
(pLS7070 and 
pLS7106) 
LS7011 CAAGTCGACGACACCAAGTCCAAAGCACAC 30 Rev Sal I 
Apc 5‘arm 
(pLS7106) 
LS7014 CAAAGCGGCCGCACTGAGACAGAGACCCCGTA 32 For Not I 
Apc 3‘arm 
(pLS7106) 
LS7016 CTTGAGCTCGTGGCTTTTTCCTTTGGGC 28 Rev Sac I 
Apc 3‘arm 
(pLS7106) 
LS7017 GTGGTACCCAACAAGTTATGGCGGAGTTC 29 For Kpn I 
Apc 5‘arm 
(pLS7106) 
LS7021 GGAGGCATGTGAAGAAACCTTG 22 For - Apc  
32P  5’ probe 
LS7029 CACGGCACTAATTTCCTGGT 20 Rev - Apc  
32P  5’ probe 
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LS7095 CGTCTTGGTTGGTTGGTTTT 20 For - p53 
32P  5’ probe 
LS7096 CGGCTACAATGGCACTTCTT 20 Rev - p53 
32P  5’ probe 
LS7124 CCGCTGCAGTGTACAGGCGCGCCATGGACAGCCTTCTGATGAAG 44 For BsrGI 
Mouse Aid 
mRNA 
LS7125 ACACACTAGTAAATCCCAACATACGAAATGC 31 Rev Spe I 
Mouse Aid 
mRNA 
LS7159 CGTGTACAACATGGACAGCCTCTTGATGAAC 31 For BsrGI 
Human AID 
mRNA 
LS7160 GGTGATCGATTTTCAAAGTCCCAAAGTACGAAATG 35 Rev Cla I 
Human AID 
mRNA 
LS7169 CCCAGAACCAAACTCAAGCC 20 For - Apc  32P  3’ probe 
LS7170 AGTTGCTGCCCCTCTATCTG 20 Rev - Apc  32P  3’ probe 
LS7251 CATCCTGGTCGAGCTGGACGGCGACGT 27 For - 
EGFP 
amplification 
LS7252 GTACAGCTCGTCCATGCCGAGAGTGAT 27 Rev - 
EGFP 
amplification 
LS7253 ACCTCATGAAGATCCTGACC 20 For - Zebrafish Actin mRNA 
LS7254 TAATCCACATCTGCTGCTGG 20 Rev - Zebrafish Actin mRNA 
LS7282 GCCACCACATCAAACCTGC 19 For - Zebrafish p53 gDNA 
LS7283 GGTCCTACAAAAAGGCTGTGA 21 Rev - Zebrafish p53 gDNA 
LS7295 CAGCCAAGTCTGTTATGTGCA 21 For - Mouse p53 gDNA (Cf) 
LS7296 CCTCCGTCATGTGCTGTGA 19 Rev - Mouse p53 gDNA (Cr) 
LS7318 GGATGGTGGTATACTCAGAGC 21 Rev - Mouse p53 gDNA (p53 Dr) 
LS7319 AGCGTGGTGGTACCTTATGAGC 22 For - Mouse p53 gDNA (p53 Df) 
LS7320 GCTATCAGGACATAGCGTTGG 21 For - Mouse p53 gDNA 
LS7328 ACAGTCGGATATCAGCCTCG 20 For - Mouse p53 mRNA 
LS7329 AGACTCCTCTGTAGCATGGG 20 Rev - Mouse p53 mRNA 
LS7341 CAGCCAAGAGTTCGCGGAG 19 For - Zebrafish p53 mRNA 
LS7342 TCGTCCTTCACCATCAGCTT 20 Rev - Zebrafish p53 mRNA 
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2.3 PLASMIDS 
Table 3: Plasmids created and used in this thesis. 
ID Insert Application Abbreviation 
pLS7070 5'arm-3xUAS-Neo-3'arm p53UAS/+ transgenic mouse  
pLS7106 5'arm-3xUAS-Neo-3'arm ApcUAS/+ transgenic mouse  
pLS7121 TALEa-Aid-wt-FL mouse p53 targeting in vitro Ta-Aid-wt 
pLS7122 TALEc-Aid-wt-FL mouse p53 targeting in vitro Tc-Aid-wt 
pLS7123 TALEe-Aid-wt-FL mouse p53 targeting in vitro Te-Aid-wt 
pLS7154 TALEa-Aid-mt-FL mouse p53 targeting in vitro Ta-Aid-mt 
pLS7155 TALEc-Aid-mt-FL mouse p53 targeting in vitro Tc-Aid-mt 
pLS7156 TALEe-Aid-mt-FL mouse p53 targeting in vitro Te-Aid-mt 
pLS7127 EGFP-AIDwt zebrafish p53 targeting in vivo EGFP-AIDwt 
pLS7129 EGFP-TALEg-AIDwt zebrafish p53 targeting in vivo EGFP-Tg-AIDwt 
pLS7130 EGFP-TALEh-AIDwt zebrafish p53 targeting in vivo EGFP-Th-AIDwt 
pLS7133 EGFP-TALEg-AIDmt zebrafish p53 targeting in vivo EGFP-Tg-AIDmt 
pLS7134 EGFP-TALEh-AIDmt zebrafish p53 targeting in vivo EGFP-Th-AIDmt 
pCDNA3-EGFP EGFP (Addgene) mouse p53 targeting in vitro EGFP 
pT2A200R150G Tol2-EGFP-Tol2  (K. Kawakami) zebrafish p53 targeting in vivo EGFP 
 
Intermediates plasmids are not shown. 
 
2.4 ANTIBODIES 
Table 4: Antibodies used in this thesis. 
Antibody Manufacturer Dilution 
Mouse monoclonal anti-AID STR9 Bernardo Reina-S-Martin 1:10,000 
Mouse monoclonal anti-Flag HRP 
conjugated A8592 – Abcam 1:10,000 
Mouse monoclonal anti-GFP 1181446001 – Roche 1:5,000 
Mouse monoclonal anti-α tubulin Sigma* 1:5,000 
Mouse monoclonal anti-vinculin Sigma* 1:10,000 
Polyclonal goat anti mouse 
immunoglobulins HRP Dako 1:10,000 
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2.5 CELL CULTURE 
2.5.1 Cell thawing and freezing 
A cryotube containing eukaryotic cells in freezing medium was thawed quickly in a water-
bath at 37 ˚C. Cells were slowly resuspended in 10 mL of warm culture medium and 
transferred to a 15 mL Falcon Tube. Cells were collected by centrifugation at 1,200 
revolutions per minute (rpm) for 5 minutes (min) and then the supernatant was removed. 
The cell pellet was resuspended in fresh medium in a volume fitting the desired cell 
density and the resuspension was transferred in a culture dish. 
For freezing, growing cells were resuspended in culture medium and collected by 
centrifugation at 1,200 rpm for 5 min and the supernatant aspired. The pellet was gently 
resuspended in 1 mL of freezing medium (10 % DMSO in complete culture medium) and 
transferred to a cryotube, which was then placed into a Nalgene® cryogenic vial freezing 
Container containing isopropanol and transferred at – 80 ˚C for 72 hours (h). Cryotubes 
were then transferred to a liquid nitrogen tank. 
 
2.5.2 Cell lines 
Cell lines used in this thesis were purchased by IFOM Cell culture facility and were 
monitored daily for morphology and cell density. Every two days, adherent cells were 
treated with 0.05 % Trypsin / 0.02 % EDTA (Try/E, Microtech®) and resuspended in PBS 
containing 0.1 % Erythrosin B and cell number was counted in a hemocytometer. Cells 
were cultured in a humidified cell culture incubator at 37 ˚C with 5 % of CO2. 
NIH3T3 cells (Mouse embryonic fibroblasts, ATCC® CRL-1658™) at passage 131 were 
maintained in Dulbecco modified Eagle’s medium high glucose (DMEM) (Lonza) 
supplemented with 10 % Calf Serum (CS) (US origin-BioWhittaker), 2 mM L-Glutamine 
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(Microtech®), 100 Units/mL Penicillin and 100 Units/mL Streptomycin (1 % P/S, 
Microtech®). 
HEK 293T (Human embryonic kidney 293 with large T antigen) cells were maintained in 
DMEM (Lonza) supplemented with 10 % Fetal Bovine Serum South American (FBS SA) 
(Biowest), 2 mM L-Glutamine (Microtech®), 1 % P/S. 
E14tg2α mouse ES cells were thawed at passage 24 on Mitomycin C-inactivated feeder 
MEFs (MMC – MEFs) and maintained in DMEM Knock out (Lonza) supplemented with 
15 % FBS ES tested (Pan Biotech), 2 mM L-Glutamine (Microtech®), 1 mM Sodium-
pyruvate (Euroclone®), 1X MEM non essential amino acids (Microtech®), homemade LIF 
(Cogentech S.c.a.r.l Transgenic Unit), 50 µM β-mercaptoethanol (Life Technologies). 
E14tg2α ES cells and MMC-MEFs were provided by the Cogentech S.c.a.r.l Transgenic 
Unit. 
 
2.5.3 Primary mouse embryonic fibroblasts generation  
TRP53/C57 heterozygous mice (Jacks et al., 1994) were bred in the IFOM animal house 
and females were checked every day for presence of plug. Females being pregnant at day 
12.5 or 13.5 were terminally anaesthetized with gradually increasing concentration of CO2. 
The entire uterus was exported and placed in PBS 1X. Next steps were performed under 
the cell culture hood with sterile surgical instruments. The uterus was washed several times 
with PBS 1X and opened from the ovary edge in order to take one embryo at the time. To 
avoid contamination within different genotypes, each embryo was treated independently. 
The placenta was opened, the yolk sac discarded and the embryo was washed 2 times in 
PBS 1X supplemented with 1 % P/S. Fetal head and liver were collected separately and 
were used to perform genotyping of the embryo. The remaining embryonic parts were 
finely minced in PBS 1X mixed with Try/E and then placed at 37 ˚C for 10 min to further 
accelerate the process of dissociation. Try/E was inactivated by adding 2 volumes of 
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complete culture medium and the suspension was transferred into a 10-cm dish 
supplemented with 10 mL of complete culture medium and grown for 1 week at 37 ˚C in a 
humidified incubator. The resulting primary mouse embryonic fibroblasts were considered 
at passage 0 and named pMEFs p0. pMEFs were cultured in a humidified cell culture 
incubator at 37 ˚C with 5 % of CO2 and 21 % of O2 and were maintained in DMEM 
(Lonza) supplemented with 10 % FBS SA (Biowest), 2 mM L-Glutamine (Microtech®), 1 
% P/S. 
 
2.5.4 Transient transfections 
NIH3T3 cells, seeded at a density of 1.1x106 cells in a 10-cm dish, were transfected the day 
after with 10 µg of plasmid diluted in Opti-MEM® (Life Technologies) mixed with 
Lipofectamine2000® (Life Technologies) transfection reagent diluted in Opti-MEM®. 
The transfection was done following manufacturer’s protocol. 
Primary p53+/- MEFs at passage 4 were seeded at the density of 3x105 cells/well in a 6-well 
plate and transfected the day after with 2 µg of plasmid DNA and FuGENE®6 (Promega) 
transfection reagents following manufacturer’s instructions. 
When two plasmids were used for co-transfection, the DNA were mixed in a ratio suitable 
for the subsequent experiment. For the sorting of GFP+ cells, the reporter plasmid 
pCDNA3-EGFP was used at 1/10 of the concentration of the other plasmids (pLS7154 and 
pLS7121). 
HEK 293T cells, seeded at the density of 2.5x105 cells/well in a 6-well plate, were 
transfected with 2 µg of plasmid DNA using the Calcium phosphate based standard 
protocol for transfection. 
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2.5.5 Soft agar assay 
Transfected NIH3T3 cells were counted after 24 h post transfection and transferred to 1.5 
mL Eppendorf tube in order to reach the density of 103 cells in 0.9 mL of DMEM 
supplemented with 20 % FBS SA. Each tube contained the cell number optimized for one 
well of a 6-well plate. Bacto™ Agar (DIFCO™ BD) solution 3 % (stored at 60 ˚C to avoid 
solidification) was mixed to DMEM + FBS SA (stored at 45 ˚C) to reach a final 
concentration of 0.6 % agar and 20 % FBS SA. 2 mL of this solution were placed in each 
well of a 6-well plate. Once solidified, 0.9 mL of cell suspensions were mixed very rapidly 
with 100 µL of agar 3 % and placed on top of the 0.6 % agar layer. The 6-well plate was 
moved carefully to a humidified incubator at 37 ˚C and cells were cultured at 37 ˚C for 4 
weeks. 
 
2.5.6 Electroporation of ES cells with pLS7070 or pLS7106 
E14tg2α ES cells at passage 25 were collected in PBS 1X. 107 cells / electroporation were 
resuspended in 400 µL of PBS 1X. Linearized plasmid DNA pLS7070 or pLS7106 was 
resuspended in 100 µL of PBS 1X and added to the ES cell suspensions by mixing well 
and avoiding bubbles formation. For each electroporation, the mix was transferred to a 
electroporation cuvette 4 mm (Bio-Rad) and electroporation was performed by Cogentech 
S.c.a.r.l Transgenic Unit with Gene Pulser Xcell™ Electroporation System (Bio-Rad) 
following the conditions listed in Table 5. 
 
Table 5: Electroporation conditions used for ES cells. 
Input Voltage 230 V 
Output Voltage 227 V 
Capacitance 500 µF 
Resistance ∞ 
Time 7.9 msec 
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Cell suspensions were incubated at room temperature (RT) for 5 min and then transferred 
to a 50 ml Falcon Tube containing complete culture medium. Electroporated ES cells 
suspension was spread on pre-seeded MMC - MEFs in a 10-cm dish and maintained in ES 
completed medium at 37 ˚C. After 24 h (day 1) the medium was supplemented with 175 
µg/mL G418 (Life Technologies) to allow the selection of neomycin-resistant cells. Once 
all the cells from the negative control (electroporation without DNA) died upon G418 
treatment (day 7), G418-resistant colonies were picked and moved to one well per colony 
in a 96-well plate. Selected colonies were expanded and cells were collected for DNA 
extraction and southern blot analysis of the recombined allele (see sections 2.6.2.1 and 
2.6.6). The first generation of clones in the 96-well plates were frozen as follow: each well 
was washed once with PBS 1X, filled with 30 µL of 0.25 % Try/E and incubated at 37 ˚C 
for 5 min. Try/E was inactivated by adding 70 µL of complete medium supplemented with 
175 µg/mL G418 and 1 % P/S. 100 µL of 2X freezing solution (20 % DMSO, 80 % FBS 
ES tested) was added by gentle mixing. The 96-well plate was covered with aluminum foil, 
placed on dry ice and stored at -80 ˚C. 
 
2.5.7 Cytogenetic analysis of ES cells selected clones for transgenic mouse generation 
Cytogenetic analysis of ES cells with the correctly homologous recombined allele was 
performed by IFOM Cell Biology Unit with Giemsa staining following standard protocols.  
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2.6 MOLECULAR BIOLOGY 
2.6.1 Cloning 
2.6.1.1 Mouse TALE-Aid-FL vectors 
Vectors pLS7154, pLS7155, pLS7156 and pLS7121, pLS7122, pLS7123 are based on the 
pBK-CMV vector. Mouse Aid wild type (wt) or Aid mutant (mt), carrying a point 
mutation in the catalytic domain (E58Q) complement DNA (cDNA) were amplified by 
polymerase chain reaction (PCR) (oligos: LS7124 - LS7125), using vectors containing 
either Aid-wt or Aid-mt (pDMF7006, pDMF7009) (see section 2.6.1.4). Three tandem flag 
sequences were generated annealing two complementary oligos (SPM431, SPM432, 
SPM433, SPM434) and further ligation of the paired oligos and inserted into pBK-CMV 
vector (resulting construct: pLS7107). pLS7107 served as the backbone for the cloning of 
the TALE-Aid fusion cDNA expression plasmids as follow: initially three TALE 
containing vectors (TALEa, TALEc, TALEe) were designed using the online tool TALE-
NT (Cermak et al., 2011; Doyle et al., 2012) and created using the Golden gate kit 
(Addgene) (Cermak et al., 2011) in collaboration with Dr. Riccardo Pecori (Dr. Silvestro 
Conticello Lab. Istituto Toscano Tumori, Italy), to recognize three different loci within 
intron 4 of mouse p53 (Table 6). For the recognition of the nucleotides A, T, G and C, the 
repeats NI, NN, NG and HD were used, respectively. Each TALE insert was ligated into 
pLS7107 and the resulting plasmids were used for insertion of the mouse Aid cDNA, and 
led to the vector construction listed in Table 3. 
 
2.6.1.2 Zebrafish EGFP-TALE-AID vectors 
Vectors pLS7129, pLS7130 and pLS7133, pLS7134 containing EGFP-TALE-AID inserts, 
were generated modifying the Tol2 vector pT2AL200R150G (Urasaki et al., 2006), which 
contains a EGFP cassette driven by an EF1α promoter, flanked by two Tol2 sites. Human 
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AID wt or AID mt (E58Q) cDNA were amplified by PCR (LS7159 - LS7160), using 
vectors containing either AID wt or AID mt cDNA (pKMS7010, pKMS7011) (see section 
2.6.1.4) and inserted into pT2AL200R150G, resulting in pLS7127 and pLS7131 
respectively. Two TALE containing vectors (TALEg, TALEh) were engineered as 
described above. The TALEs cDNA were designed to recognize two different loci within 
intron 6 of zebrafish p53 (Table 6). TALEs fragments were inserted into pLS7127 and 
pLS7131 to create the final plasmids listed in Table 3. 
 
Table 6: TALE design. 
 
2.6.1.3 p53UAS and ApcUAS targeting vectors 
A targeting vector containing a neomycin cassette flanked by two loxP sites was used as a 
backbone (pBML3) to create vectors pLS7070 and pLS7106 (Table 3). Three UAS sites 
were made by annealing sense (LS6988) and anti-sense (LS6989) UAS encoding oligos, 
and ligated into bML3 vector (pLS7063). For p53 targeting, 5’ homology arm of 3.9 kb 
and 3’ homology arm of 3.5 kb were amplified by PCR using gDNA from E14tg2α ES 
cells as template (5’ arm: LS6917 - LS6920; 3’ arm: LS6921 - LS7924) and TaKaRa LA 
TALE ID Species Target sequence Strand Length (nt) RVD sequence 
TALEa Mouse 
T 
GTCCCTCCCACTTTG
GCCT 
Minus 19 
NN NG HD HD HD NG HD HD 
HD NI HD NG NG NG NN NN 
HD HD NG 
TALEc Mouse 
T 
CCCAGTCCTCTCTTTG
CT 
Plus 18 
HD HD HD NI NN NG HD HD 
NG HD NG HD NG NG NG NN 
HD NG 
TALEe Mouse 
T 
GGAAGTAAGACCCCT
TCT 
Plus 18 
NN NN NI NI NN NG NI NI NN 
NI HD HD HD HD NG NG HD 
NG 
      
TALEg Zebrafish 
T 
ACGGATAGTGTAACT
CAAT 
Plus 19 
NI HD NN NN NI NG NI NN 
NG NN NG NI NI HD NG HD 
NI NI NG 
TALEh Zebrafish 
T 
GCAACTATACTTCAC
TCAT 
Minus 19 
NN HD NI NI HD NG NI NG NI 
HD NG NG HD NI HD NG HD 
NI NG 
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PCR kit for amplification (TaKaRa Clontech) with standard amplification program (see 
section 2.6.1.4). PCR products of 5’ and 3’ arms were ligated into pLS7063 sequentially, 
generating the final vector pLS7070. For Apc targeting, 5’ homology arm of 4.3 kb and 3’ 
homology arm of 3.7 kb were amplified following the same protocol described above for 
p53 (5’ arm: LS7017 - LS7011; 3’ arm: LS7014 – LS7016) and ligated sequentially into 
pLS7063 to generate the final vector pLS7106. 
 
2.6.1.4 PCR amplification 
a) TALE-AID plasmids 
PCR from template plasmids (pDMF7006, pDMF7009, pKMS7010, pKMS7011) was 
performed in a total volume of 50 µL as follows: 50 ng of plasmid DNA were amplified in 
a reaction buffer composed of 1X Pfu Buffer, 0.25 mM dNTPs (Promega), 0.25 pmol/µL 
of each oligo and 1.25 Units of Pfu Polymerase (Promega). The amplification program 
consisted in: initial denaturation at 95 ˚C for 2 min, 15 cycles of 95 ˚C for 30 seconds 
(sec), 57 ˚C for 30 sec and 72 ˚C for 30 sec, and final extension step at 72 ˚C for 5 min. 
PCR was carried out using the thermal cycler GeneAmp® PCR system 9700 from Applied 
Biosystems®. 
b) p53UAS and ApcUAS targeting  
PCR using ES cell genomic DNA as template was performed in a total volume of 50 µL. 
For each reaction 500 ng of template DNA was diluted in a reaction buffer composed of 
1X LA PCR Buffer II (TaKaRa Clontech), 0.25 mM dNTPs (Promega), 0.2 pmol/µL of 
each oligo and 2.5 Units of TaKaRa La Taq polymerase (TaKaRa Clontech). 
Amplification program: initial denaturation at 94 ˚C for 1 min, 10 cycles of: denaturation 
at 98 ˚C for 10 sec, annealing with decreasing temperature (touchdown from 64 ˚C down 
by 1 ˚C per cycle) and amplification at 68 ˚C for 6 min. Then 25 cycles at 98 ˚C for 10 sec, 
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gradient from 55 ˚C to 59 ˚C for 1 min and 68 ˚C for 6 min was applied. PCR was carried 
out using an Eppendorf Mastercycler gradient PCR machine. 
 
2.6.1.5 Gel purification 
For purification, PCR products were loaded onto agarose gels and after electrophoresis, 
corresponding bands were excised and purified with Wizard® SV Gel and PCR Clean-Up 
System (Promega), according to the manufacturer’s instructions. Elution from columns 
was performed in 50 µL of ddH2O.  
 
2.6.1.6 Fragment preparation by enzymatic digestion and gel purification 
Samples were digested in a total reaction volume of 30 µL, by diluting 1 µg of template 
plasmid DNA in a restriction enzyme compatible 1X NEB buffer and 10 Units of 
restriction enzyme (NEB: NEW ENGLAND Biolabs® Inc). Digestions were incubated at 
the enzyme recommended temperature for 3 h. After incubation the enzymes were heat 
inactivated at 65 – 80 ˚C for 20 min and the DNA was treated with 0.5 Units of Calf 
Alkaline Phosphatase (CIP) from NEB at 37 ˚C for 1 hour (h). Digested fragments were 
separated by agarose gel electrophoresis and purified as described above. 
 
2.6.1.7 Single strand oligo annealing 
Single strand oligonucleotides were resuspended in dH2O to reach a final concentration of 
100 pM. Each oligo was subjected to phosphorylation reactions. 100 pmol of each oligo 
were diluted in 1X T4 DNA ligase buffer (NEB) and 10 Units of T4 polynucleotide kinase 
(PNK)  (NEB) in 20 µL total volume. Reactions were incubated at 37 ˚C for 1 h, 
complementary phosphorylated oligos were mixed (1:1) and 10 mM Tris-HCl pH 8 
solution was added to reach a final volume of 100 µL. Oligos were annealed as follows: 
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denaturation: incubation of the mix in a heat block at 95 ˚C for 1 min; annealing: the oligo 
mix still placed into the heat block was allowed to cool down slowly to RT by placing the 
heat block on the lab bench after denaturation. 
 
2.6.1.8 DNA ligation 
Ligation reaction was performed in 20 µL as follows: 2 µL of 10X T4 DNA ligase buffer 
(NEB), approximately 50 ng of digested backbone vector and DNA insert in molar excess 
of 3 – 5 times compared to backbone. 400 Units of T4 DNA ligase (NEB) were added to 
the reaction and samples were incubated for 1 h at RT. Alternatively, for blunt end 
ligation, the ligation reaction was performed at 16 ˚C overnight (o/n). 
 
2.6.1.9 Bacterial transformation and Midi preparation of plasmid DNA 
E. coli transformation was done as follow: 5 µL of ligation product (plasmids) was gently 
mixed with 50 µL of One Shot® TOP10 Chemically (Life Technologies) or Subcloning 
Efficiency™ DH5α™ Competent E. coli and transformations were performed following 
the manufacturer’s instructions. 
For a Midi-preparation of plasmid DNA 100 mL of LB medium containing antibiotics was 
inoculated with a single E. coli colony and bacteria were grown for 12 h at 37 ˚C upon 
shaking. Bacterial cells were harvested by centrifugation of the suspension culture at 5,000 
rpm for 15 min at RT in a Beckman JA-14 rotor (Beckman Coulter, Inc), cells were 
resuspended and DNA was extracted and purified using PureYeld™ Plasmid Midiprep 
System (Promega) following manufacturer’s instructions. 
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2.6.2 Nucleic acid extractions and amplification 
2.6.2.1 DNA extraction 
a) ES cells  
Complete culture medium from ES cell clones grown in 96-well plates (after 
electroporation with pLS7070 and pLS7106 plasmids) was removed and cells were 
covered and incubated with 50 µL of Lysis buffer for 3 h in a humidified chamber. Plates 
were transferred to RT and incubated for 1 h, and then NaCl/EtOH precipitation was 
performed.  Briefly, 1.5 µL of NaCl 5 M and 100 µL of cold EtOH 100 % were added to 
each well and the 96-well plate was incubated for 2 – 3 h at RT upon shaking. The 
supernatant was discarded inverting carefully the plate and each well was washed two 
times with 100 µL of EtOH 70 %. After centrifugation at 1,200 rpm for 5 min, the 
supernatant was discarded and the resulting DNA pellet, upon air-drying for 20 min, was 
resuspended in 30 µL of Digestion mix (1X restriction enzyme buffer, 1X BSA, 1 mM 
spermidine, NEB restriction enzyme 1 Unit/µg of DNA) and incubated o/n at 37 ˚C for 
subsequent southern blot analysis (see section 2.6.6).  
b) Zebrafish caudal fin clip, mouse tail biopsy, mouse embryo tissues 
Zebrafish caudal fin biopsies or mouse tissue biopsies were digested in 500 µL of lysis 
buffer at 56 ˚C in Thermomixer compact (Eppendorf) o/n upon vigorously shaking. DNA 
was precipitated adding an equal volume of isopropanol and collected by centrifugation at 
13,000 rpm for 10 min. Supernatant was removed and the DNA pellet, after air-drying for 
few minutes, was resuspended in TE 1X. 
c) pMEFs 
Transiently transfected pMEFs clones expanded to a 6-well plate were treated with 500 µL 
Try/E and placed at 37 ˚C for 5 min to allow the process of dissociation. Try/E was 
inactivated adding 9 volumes of complete culture medium and the suspension was 
harvested by centrifugation at 1,200 rpm at 4˚C for 5 min. The cell pellet was digested in 
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500 µL of Lysis buffer at 56 ˚C as described above. The DNA was extracted with 
Phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma-Aldrich) following standard 
protocols. The resulting pellet DNA was resuspended in 100 µL of TE 1X. 
 
2.6.2.2 RNA extraction 
a) RNA extraction of GFP+ sorted NIH3T3 cells and zebrafish larvae for Ion Torrent™ 
analysis 
After FACS sorting (see section 2.8.1), 6 – 8x105 GFP+ NIH3T3 cells and mock control 
sample were collected by centrifugation at 1,200 rpm at 4 ˚C for 5 min. The supernatant 
was discarded and RNA from cells was isolated using All Prep DNA/RNA Mini kit 
(QIAGEN) following manufacturer’s instructions, with the centrifugation steps performed 
at 13,000 rpm for 1 min at RT. RNA was eluted in 30 µL of H2O and quantified by 
microvolume UV spectrophotometer (NanoDrop® ND-1000). 
20 injected zebrafish embryos at 24 hours post fertilization (hpf) were lysed and 
homogenized in RLT plus buffer (QIAGEN), by passing at least 10 times through a 1 mL 
RNAse-free syringe and RNA was isolated using All Prep DNA/RNA mini Kit (QIAGEN) 
following manufacturer’s protocol and centrifugation steps as described above. 
b) Others (zebrafish larva, mouse organs and pMEFs) 
Total RNA from one zebrafish larva at 5 days post fertilization (dpf), mouse organs or 
6x105 of pMEFs cells were isolated using TRIzol® reagent (Life Technologies), following 
manufacturer’s instructions. Where necessary, homogenization of the sample was 
facilitated by passing the lysate at least 5 times through a 1 mL RNAse-free syringe.  The 
RNA pellet was resuspended in 30 µL of 10 mM Tris-HCl pH 7.4 and incubated 20 min at 
55 ˚C on a Thermomixer compact (Eppendorf) prior to DNAse I treatment. Each sample 
was mixed with 1X DNAse I buffer (Roche), RNasin® 60 Units (Promega), 4.5 Units 
DNAse I (Roche) and incubated for 30 min at 37 ˚C in a Thermomixer compact. After 
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DNAse I digestion samples were purified with TRIzol® reagent according to 
manufacturers protocol, and RNA was dissolved in 30 µL of 10 mM Tris-HCl pH 7.4. 
RNA amount was measured with microvolume UV spectrophotometer (NanoDrop® ND-
1000) and RNA quality was assessed by agarose gel electrophoresis (see section 2.6.4). 
 
2.6.2.3 cDNA synthesis 
The cDNA was obtained by reverse transcription (RT) of RNA using the reverse 
transcriptase SuperScript II® kit (Life Technologies) and oligo dT (Life Technologies). 
RNA for RT+ and RT- reactions (1 µg or 500 ng of RNA each) was added to a mastermix 
of 1X Buffer FS (Life Technologies), 5 mM dithiothreitol (DTT) (Life Technologies), 8 
Units RNAsin® (Promega), 0.4 mM of each dNTPs, 2.5 µM oligo dT and distilled water 
DNAse/RNAse free (Life Technologies). 200 Units of SuperScript II® reverse 
transcriptase were added to RT+ samples, while the equivalent amount of ddH2O was 
added to the RT- samples. cDNA synthesis was performed in the thermal cycler 
GeneAmp® PCR system 9700 (Applied Biosystems®) according to the following 
protocol: 37 ˚C for 10 min, 50 ˚C for 40 min and 55 ˚C for 10 min. cDNA was used for 
subsequent PCR reactions (RT-PCR). 
 
2.6.3 PCR reactions (genotyping, gDNA analysis, RT-PCR and qRT-PCR) 
a) Genotyping of adult mice and embryo, adult zebrafish and larvae, and gDNA analysis of 
pMEFs 
Genotyping of animals and gDNA analysis of p53 on pMEFs was performed by PCR using 
gDNA extracted from tissue biopsies or cells as template. PCR were performed using the 
GoTaq G2 kit (Promega). Each PCR reaction was assembled in a total volume of 25 µL: 
100 ng of DNA were amplified in a reaction mix composed of 1X GoTaq Buffer, 0.2 mM 
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dNTPs, 0.2 pmol/µL of each oligo and 0.5 Units of GoTaq G2 polymerase. PCR reaction 
was performed in the thermal cycler GeneAmp® PCR system 9700 (Applied 
Biosystems®) and the amplification programs and oligos used are listed in Table 7 
according to the species and the gene amplified. 
 
Table 7: PCR conditions and oligos used for genotyping of animals gDNA and analysis of pMEFs 
 Gal4-Aid (transgenic mouse) 
Human AID (adult zebrafish 
and larval embryos) p53 (p53
+/- mouse) 
Oligos DMF1828 – DMF 1829 LS7159 – LS7160 LS7318 – LS7139 – LS7320 
PCR 
program 
95 ˚C  2 min 
95 ˚C  45 sec | 
56 ˚C  45 sec |  x 32 cycles 
72 ˚C 30 sec  | 
72 ˚C 5 min 
95 ˚C   2 min 
95 ˚C   30 sec  | 
60 ˚C   30 sec  |    x 30 cycles 
72 ˚C   1 min    | 
72 ˚C   5 min 
95 ˚C   2 min 
95 ˚C   30 sec  | 
55 ˚C   30 sec  |    x 35 cycles 
72 ˚C   1  min  | 
72 ˚C   5 min 
 p53 (adult zebrafish and larval embryos)  
Oligos  LS7282 – LS7283  
PCR 
program  
95 ˚C   2 min 
95 ˚C   30 sec  | 
60 ˚C   30 sec  |    x 30 cycles 
72 ˚C   1 min   | 
72 ˚C  5 min 
 
 p53 for pMEFs analysis 
Oligos LS7328 – LS6934 LS6932 – LS6920 LS7295 – LS7296 
PCR 
program 
95 ˚C     2 min 
95 ˚C     30 sec  | 
55.5 ˚C  30 sec  |  x 35 cycles 
72 ˚C      40 sec | 
72 ˚C       5 min 
95 ˚C     2 min 
95 ˚C     30 sec  | 
55.5 ˚C  30 sec  |  x 35 cycles 
72 ˚C       1 min | 
72 ˚C       5 min 
95 ˚C     2 min 
95 ˚C     30 sec  | 
55.5 ˚C  30 sec  |  x 35 cycles 
72 ˚C       1 min | 
72 ˚C       5 min 
Oligos LS7319- LS7318 LS6945 – LS6951  
PCR 
program 
95 ˚C     2 min 
95 ˚C     30 sec  | 
55.5 ˚C  30 sec  |   x 35 cycles 
72 ˚C      1 min | 
72 ˚C      5 min 
95 ˚C     2 min 
95 ˚C     30 sec  | 
55.5 ˚C  30 sec  |   x 35 cycles 
72 ˚C      1 min | 
72 ˚C      5 min 
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b) RT-PCR 
Each RT-PCR reaction was performed using the cDNA retro-transcribed from total RNA 
as template. The reaction was performed in a volume of 50 µL as follow: 100 ng of cDNA 
were diluted in a reaction buffer composed of 1X Pfu Buffer, 0.25 mM dNTPs (Promega), 
0.25 pmol/µL of each primer and 1.25 Units of Pfu Polymerase (Promega). RT-PCR 
reaction was performed in the thermal cycler GeneAmp® PCR system 9700 (Applied 
Biosystems®) and the amplification programs and oligos used are listed in Table 8 
according to the species and the gene amplified. 
 
Table 8: PCR conditions and oligos used for mice and zebrafish genes expression. 
  p53 (mouse NGS analysis) 
 Gapdh (mouse NGS 
analysis) 
Gal4-AID (tissue 
expression) 
Gapdh (tissue 
expression) 
Oligos LS7328 – LS7329 SP3033 - SP3018 DMF1828 – DMF 1829 SP3033 – SP3034 
PCR 
program 
95 ˚C  2 min 
95 ˚C  30 sec | 
57 ˚C  30 sec |  x 30  
                          cycles 
72 ˚C 1 min  | 
72 ˚C 5 min 
95 ˚C  2 min 
95 ˚C  30 sec  | 
55 ˚C 30 sec   |  x 30  
                             cycles 
72 ˚C  30 sec | 
72 ˚C  5 min 
95 ˚C  2 min 
95 ˚C  45 sec | 
56 ˚C  45 sec |    x 30  
                           cycles 
72 ˚C 30 sec  | 
72 ˚C 5 min 
95 ˚C  2 min 
95 ˚C  30 sec | 
55 ˚C  30 sec | x 30 
                         cycles 
72 ˚C 30 sec  | 
72 ˚C 5 min 
 Human AID (zebrafish) 
EGFP (zebrafish 
tissue expression) 
β-actin (NGS analysis 
and tissue expression) p53 (NGS analysis) 
Oligos Same as Table 7 LS7251 – LS7252 LS7253 – LS7254 LS7341 – LS7342 
PCR 
program  
95 ˚C   2 min 
95 ˚C   30 sec | 
60 ˚C   30 sec |    x 30 
                          cycles 
72 ˚C   1 min  | 
72 ˚C  5 min 
95 ˚C  2 min 
95 ˚C  30 sec | 
58 ˚C  40 sec |    x 30 
                           cycles 
72 ˚C 30 sec  | 
72 ˚C 5 min 
95 ˚C  2 min 
95 ˚C  30 sec | 
55 ˚C  30 sec |   x 30 
                          cycles 
72 ˚C 1 min   | 
72 ˚C 5 min 
 
c) Quantitative Real-Time PCR (qRT-PCR) 
Quantitative Real-Time PCR reactions were performed in triplicates in a final volume of 
10 µl per reaction in 96 well plates (Euroclone®). 50 ng of cDNA template were diluted in 
a reaction buffer composed of 5 µl of GoTaq qPCR Master Mix (Promega) and 0.2 
pmol/µL of each primer. Standard curves were prepared by making serial dilutions of 
cDNA from mock transfected cells. Amplification programs and oligos used are listed in 
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Table 9. The reaction was monitored in the LightCycler® 480 Real-Time PCR System 
(Roche) and the data were acquired using the LightCycler® 480 software version 1.5 
(Roche). Gene expression levels were normalized to Gapdh mRNA. Transcript fold 
enrichment was calculated by 2-ΔΔCt method (Livak and Schmittgen, 2001). 
 
Table 9: PCR conditions and oligos used for qRT-PCR. 
 p53 Gapdh 
Oligos LS7295-7296 SP3033-3034 
qRT-PCR 
program 
95 ˚C            10 min 
 
95 ˚C            10 sec   | 
62 ˚C            10 sec   |  x  45 cycles                           
72 ˚C            15 sec   | 
 
95˚C              5 sec 
60 – 97 ˚C  1.2˚C/min 
 
2.6.4 Agarose gel electrophoresis 
Separation of PCR fragments by size was performed by agarose gel electrophoresis in TBE 
1X buffer. The agarose gel was obtained by dissolving agarose (0.7 -1.5 %) (GellyPhorLE, 
Euroclone®) in TBE 1X and 1X GelRed™ nucleic acid gel stain (Biotium). Size of 
fragments was determined by a 100 bp or 1 kb DNA ladder (Promega) and visualized 
using Molecular Imager® ChemiDoc™ XRS+ Imaging system (Bio-Rad). 
Quality of isolated RNA was monitored by agarose gel electrophoresis in MOPS 1X 
buffer. An aliquot of RNA was mixed 1:1 with 2X RNA loading dye (50 % Formamide, 20 
% formaldehyde, MOPS 2X, 0.05 mg/mL ethidium-bromide) and denatured at 65 ˚C for 
15 min. Reactions were quenched by placing the sample on ice for 5 min and then RNA 
samples were loaded on a denaturing 1 % agarose MOPS gel. 
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2.6.5 DNA sequencing 
2.6.5.1 Sanger sequencing 
DNA Sanger sequencing reactions were performed by Cogentech S.c.a.r.l Sequencing 
Unit. The dRhodamine Dye Terminator Ready Reaction Cycle Sequencing Kit 
(Thermofisher) was used and the samples were processed on a 16 capillary 3130xl Genetic 
Analyzers (Applied Biosystem). 
 
2.6.5.2 Next-generation sequencing (NGS) 
Ion Torrent™ NGS on PCR fragments was performed by the IFOM Genomic Unit.  
a) Ion Proton™System 
Libraries for p53 and Gapdh cDNA amplicons derived from GFP+ NIH3T3 cells or p53 
and β-actin amplicons derived from 20 zebrafish embryos were prepared following the 
manufacturer protocols for genome sequencing with the Ion Proton™ sequencer (Life 
Technologies). Briefly ~ 480 - 680 ng of mouse cDNA and ~ 450 – 3000 ng of zebrafish 
cDNA were mechanically sheared to ~ 200 bp with Covaris S220/E220 Focused-
ultrasonicator (Covaris, Inc) for 6 min, end-repaired and adapter-ligated using the 
NEBNext® Fast DNA Library Prep Set for Ion Torrent™ (NEW ENGLAND Biolabs® 
Inc) and adapter barcode Ion Xpress Barcode Adaptors 1-16 (Life Technologies). After 
adapter ligation, each sample was size-selected using AMPure XP Bead (Beckman 
Coulter, Inc), and enriched by PCR reaction. A SPRI cleanup with a 1.5X Bead:DNA ratio 
was performed post amplification and final libraries were eluted in 25 µL. Libraries were 
quantified and checked for size on an Agilent Bioanalyzer with HS DNA kit (Agilent, 
Santa Clara, CA). Each size selected library was diluted to a final concentration of 11 pM 
and clonally amplified using the Ion Proton™ 200™Template Kit v3 (Life Technologies). 
After emulsion PCR, DNA positive Ion Sphere Particles (ISPs) were recovered and 
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enriched according to standard protocols with the Ion OneTouch™ 2 Instrument (Life 
Technologies). A sequencing oligo was annealed to DNA positive ISPs and the sequencing 
polymerase bound, prior to loading of ISPs into Ion P1 v2 sequencing chips. Six libraries 
were loaded onto one P1 sequencing chips and run on a Ion Proton™ Machine according 
to the Ion Proton™ Sequencing 200 Kit v3 protocol. 
The second Ion Proton™ run of mouse p53 cDNA, differs from the one already described 
in the kit used for clonal amplification of the size-selected libraries, the chip used and the 
protocol applied for sequencing. Each size-selected library was diluted to a final 
concentration of 11 pM and clonally amplified using the Ion Proton™ Hi-Q™Template 
Kit (Life Technologies) with Ion OneTouch™ 2 instrument (Life Technologies). 
Sequencing of the samples was conducted on one P1 sequencing chip loaded with four 
libraries, according to the Ion Proton™ Hi-Q Sequencing Kit Protocol. Samples were run 
on an Ion Proton™ sequencer. 
b) Ion PGM™System 
Libraries for p53 cDNA amplicons derived from GFP+ NIH3T3 cells, were prepared 
following the manufacturer protocols for genome sequencing with the Ion 
PGM™sequencer (Life Technologies) as already described for Ion Proton™ System. Each 
size-selected library was diluted to a final concentration of 25 pM and clonally amplified 
using the Ion PGM™Hi-Q™Template Kit (Life Technologies). After emulsion PCR, DNA 
positive ISPs were recovered and enriched according to standard protocols with the Ion 
OneTouch™ ES Instrument (Technologies). A sequencing oligo was annealed to DNA 
positive ISPs and the sequencing polymerase bound, prior to loading of ISPs into Ion 316 
sequencing chips. Sequencing of the samples was conducted on one 316 sequencing chip 
loaded with six libraries, according to the Ion PGM™ Hi-Q Sequencing Kit Protocol. The 
chip was run on an Ion Personal Genome Machine. 
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2.6.6 Southern blot analysis 
Southern blot analysis was performed on ES cells previously electroporated with linearized 
pLS7154 or pLS7106, to assess if the homologous recombination occurred at the desired 
genomic locus. DNA (3 µg) extracted from ES cells was digested with Hind III or EcoRV 
(p53 5’ and 3’ arms respectively), or with Psi I – Cla I and Bgl II (Apc 5’ and 3’ arms 
respectively) in 96-well plates. Digested DNA was loaded onto a 0.8 % agarose gel and 
electrophoresis was performed o/n at 4 ˚C at 80 Volts. After the run, incubation of the gel 
for 1 h at RT in denaturing solution upon slow agitation allowed for the denaturation of the 
DNA in the gel. Subsequently, capillary transfer of the DNA from the gel to a Hybond-N+ 
(Amersham Biosciences) membrane was performed o/n in SSC 20X (EuroClone) buffer 
according to standard protocols. Membranes were then exposed twice to 0.12 joules UV 
light using the UV-stratalinker 2400 (Stratagene) and then the membrane was placed in a 
roller bottle, pre-incubated with pre-warmed PerfectHyb Plus (Sigma) hybridization 
solution for 1 h at 65 ˚C upon agitation on a wheel inside in the hybridization oven. A 
radiolabelled probe was added to the roller bottle and hybridization was allowed o/n at 65 
˚C. The membrane was washed 3 times in washing buffer at 65 ˚C and the radioactive 
signal was detected with Thypoon TRIO (GE Healthcare) phospho-imager. Images were 
acquired with ImageQuantTL Software (GE Healthcare). 
The radiolabelled probe was prepared by PCR using mouse ES cells genomic DNA as a 
template. Table 10 reports the oligos used for the creation of p53 and Apc specific probes 
and the PCR program applied. Probes were labeled with dCTP [α-32P] 6000 Ci/mMol 
(PerkinElmer) using the Prime-a-Gene® Labeling system kit (Promega) following 
manufacturer’s instructions. Radioactive probes were purified from free 32P dCTP with GE 
Illustra Probequant G-50 Micro columns (GE Healthcare), following manufacturer’s 
protocol.  
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Table 10: PCR conditions and oligos used for southern blot probe generation. 
 p53 5’ probe p53 3’ probe Apc 5’ probe Apc 3’ probe 
Oligos LS7095 – LS7096 LS6946 – LS6951 LS7021 – LS7029 LS7169 – LS7170 
PCR 
program 
94 ˚C  2 min 
94 ˚C  30 sec | 
55 ˚C  30 sec |  x 25  
                      cycles 
72 ˚C 30 sec  | 
72 ˚C 5 min 
94 ˚C  2 min 
94 ˚C  30 sec   | 
55.5 ˚C 30 sec | x 35   
                       cycles 
72 ˚C  30 sec   | 
72 ˚C  5 min 
94 ˚C  2 min 
94 ˚C  30 sec   | 
59 ˚C 30 sec    |   x 25   
                           cycles 
72 ˚C  30 sec   | 
72 ˚C  5 min 
94 ˚C  2 min 
94 ˚C  30 sec | 
56 ˚C  45 sec |  x 25 
                      cycles 
72 ˚C  30 sec | 
72 ˚C  5 min 
 
 
2.7 BIOCHEMISTRY  
2.7.1 Protein lysates 
Transfected cells (see section 2.5.4) were harvested 24 h post transfection and lysed for 
immunoblot assay. NIH3T3 cells were harvested at the density of 2x106 cells in a 10-cm 
dish, while HEK 293T cells and pMEFs were harvested at the density of 6x105 in a 6-well 
plate. Cells were washed on the plate with PBS 1X and then placed on ice covered with 1 
mL of PBS 1X. Cells were scraped and collected in a 1.5 mL Eppendorf tube. After 
centrifugation at 5,000 rpm for 5 min at 4 ˚C, supernatant was removed and the pellet was 
resuspended in 60 – 100 µl of RIPA-02 buffer and incubated on ice for 10 min. After 
incubation, samples were sonicated for 5 cycles of 15 sec each using the Bioruptor™ Next 
Gen (Diagenode) and lysates were stored at - 80 ˚C. 
 
2.7.2 Immunoblot 
Sonicated protein lysates (20 µl) were mixed with Laemmli buffer to a final concentration 
of 1X Laemmli supplemented with EDTA-free protease inhibitors 1X, denatured at 95 ˚C 
for 5 min and loaded on a Mini-PROTEAN® TGX™ Precast Gel 4 – 20 % (Bio-Rad). 
Electrophoresis was performed for 30 min at 200 Volts in 1X Running Buffer. Proteins 
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were transferred from the gel to a 0.2 µm nitrocellulose membrane by Trans-Blot® 
Turbo™ Transfer System (Bio-Rad) for 7 min. The membrane was blocked with 5 % milk 
in TBS-T for 1 h at RT shaking to saturate the non-protein containing areas and to prevent 
unspecific binding of the antibody (indicated in Table 4). After blocking, milk was 
removed and the membrane was incubated with the specific antibody o/n at 4 ˚C upon 
agitation. After 3 washes for 10 min with TBS-T 1X shaking, the membrane was incubated 
with the specific secondary antibody for 1 h at RT upon agitation. This step was not 
performed if the membrane was incubated with an HRP-linked primary antibody. After 3 
washes for 10 min in TBS-T 1X, the membrane was incubated with Amersham™ ECL™ 
RPN2016 (GE Healthcare) according to manufacturer’s instructions and the signals were 
detected by different exposure using Molecular Imager® ChemiDoc™ XRS+ Imaging 
system. 
 
2.8 IMAGING 
2.8.1 Fluorescence-activated cell sorting (FACS) 
NIH3T3 cells (6 – 8 x106 cells/transfection) were collected 48 h after transfection and 
washed in PBS 1X. Cells were resuspended to reach the density of 5x106/mL in FACS 
buffer on ice. Cells were sorted by IFOM Imaging Unit with FACSAriaTM III sorter (BD 
Bioscience) and collected in Sorting buffer for subsequent RNA analysis.  
pMEFs p53+/- at passage 5 (9x106 cells/transfection) were harvested 72 h post transfection 
and washed with PBS 1X. Cells were resuspended to reach the density of 5x106/mL in 
FACS buffer II on ice. Isolation of GFP+ cells was performed by IFOM Imaging Unit with 
FACSAriaTM III sorter (BD Bioscience) and cells were collected in Sorting buffer II. GFP+ 
cells were re-seeded at the density of 300 cells/well in a 96-well plate and maintained in 20 
% conditioned medium to allow for complete recovery. Conditioned medium was prepared 
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as follows: complete medium from p53-/- pMEFs was harvested every 48 h and filter with 
0.22 µm sterile filters. 
 
2.8.2 Bright field microscopy 
a) Zebrafish embryos 
Injected embryos at 24 hpf  (see section 2.9.4.1) were anaesthetized in 15 mg/L Tricaine 
(Sigma) in a 10-cm dish and decoryonated manually, by using two 1 mL insulin syringes. 
Embryos were placed on a layer of methylcellulose 3 % in E3 water. Morphological 
analysis, EGFP and Dextran Rhodamine B (Molecular Probes™) (Rhddext) expression 
were evaluated using Olympus SZX12 stereomicroscope. Image acquisitions were 
performed at 22.5X objective for GFP and Rhddext expression or 40X  objective to 
evaluate developmental defects. 
b) Adult zebrafish 
Images of haematoxylin and eosin (H&E) stains of fish paraffin sections (see section 2.9.7) 
were acquired with an Olympus SZX12 stereomicroscope at 7X objective, while images at 
10X, 20X of specific organs were acquired with a NIKON Eclypse 90i microscope. 
Image analysis was performed with NIS-Element image software D 3.1 (Nikon).  
Both a) and b) procedures were performed in collaboration with the IFOM Zebrafish Unit. 
c) HEK 293T transfected cells 
EGFP expression in transfected HEK 293T cells was evaluated using EVOS™ fl Digital 
Inverted Fluorescence Microscope (AMG). Image acquisitions were performed at 10X. 
 
2.8.3 Confocal microscopy 
Embryos at 24 hpf were anaesthetized in 15 mg/L Tricaine (Sigma) in a petri dish, 
decoryonated manually with two 1 mL insulin syringes and mounted in 1.2 % low-melting 
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agarose in E3 water. Image acquisition was performed at 40X water immersion objective 
on a Leica TCS SP2 confocal microscope. Image analysis was done with Leica LCS 
software in collaboration with the IFOM Zebrafish Unit. 
 
2.9 IN VIVO TECHNIQUES 
All the procedures performed on live animals were performed according to the Italian 
Government rules and were authorized by the Italian Minister of Health (project 71/2015 
PR, project 02/13). 
 
2.9.1 Mouse strains 
The CMV-Gal4-Aid mouse is described in (Franchini et al., 2014) while TRP53/C57 
mouse strain (Jacks et al., 1994) was a gift from Dr. Pier Giuseppe Pelicci (IEO, Milan). 
The Deleter-Cre mouse strain (Schwenk et al., 1995) was a gift from Dr. Stefano Casola 
(IFOM, Milan). C57BL/6J and CD1 mouse strains were purchased from Charles River 
Laboratories Italia, SRL. 
 
2.9.2 Organ collection from CMV-Gal4-Aid mouse strains 
Organs were obtained from 16-weeks old CMV-Gal4-Aid transgenic mice. Mice were 
terminally anesthetized with increasing concentrations of CO2 in the IFOM animal house. 
Organs were exported with sterile surgical instruments and placed in 10 mL of PBS 1X. 
Organs were then smashed and passed through a Falcon 70 µm cell strainer filter (Becton 
Dickinson, USA) with 5 mL of cold PBS 1X and suspensions were collected in a 50 mL 
Falcon tube. Cell suspensions were centrifuged at 1,200 rpm at 4 ˚C for 10 min and the 
pellet resuspended in 1 mL of hypotonic lysis buffer to achieve erythrocytes lysis. After 10 
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min of incubation on ice, the reaction was inactivated by adding 9 volumes of cold PBS 
1X. After centrifugation at 1,500 rpm for 10 min at 4 ˚C, cells were resuspended in PBS 
1X, divided into aliquots, collected by centrifugation and stored at -80 ˚C. 
 
2.9.3 Injection of transgenic ES cells into C57BL/6J female blastocyst 
Microinjection of the selected homologously recombined ES cells into C57BL/6J female 
blastocysts was performed by Cogentech S.c.a.r.l Transgenic Unit using a NT88 
Micromanipulator System (Nikon). Blastocysts were implanted into pseudo-pregnant CD1 
females and pregnancy monitored over-time. 
 
2.9.4 Zebrafish embryo microinjection 
Injection procedures and zebrafish handling was done in collaboration with the IFOM 
Zebrafish Unit. 
 
2.9.4.1 Transient injections 
Vectors (40 pg) and Rhddext (5 pg) in Danieau solution were co-injected into wild type 
(AB) fertilized one cell-stage embryos. 200 – 300 fertilized eggs were injected for each 
construct and were maintained in a petri dish with water E3 at 28.5 ˚C. Analysis of 
developmental problems or of EGFP and Rhddext expression was performed at 24 hpf. 
The micro injector used was composed of the injection pump PICOSPRITZER® III 
(Parker Hannifin Corporation) and the MN-153 micromanipulator (NARISHIGE). 
 
2.9.4.2 Generation of transgenic lines 
The transposase messenger RNA (mRNA) (70 pg) and zebrafish specific plasmids (40 pg) 
were co-injected into wt (AB) fertilized one cell-stage embryos. 200 – 300 embryos were 
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injected for each construct and maintained in a petri dish with water E3 at 28.5 ˚C until 5 
dpf. At 6 dpf the larvae were transferred into aquarium tanks of the IFOM Zebrafish Unit 
with water and room temperature of 28.5 ˚C. The micro injector was used as described 
above. 
 
2.9.5 Fin clip of larval embryos  
Genotyping of zebrafish larvae at 72 hpf was performed via transection of the embryonic 
caudal fin, followed by rapid genomic DNA extraction and genotyping by PCR (Wilkinson 
et al., 2013). Briefly, larvae were anaesthetized in 15 mg/L Tricaine (Sigma) for 2 min and 
transferred on a lid of a petri dish that had been lined with a strip of autoclave tape. Under 
the Olympus SZX12 stereomicroscope, the caudal fin within the pigment gap of the larva 
was removed using a microsurgical knife (World Precision Instruments). The fin clip 
biopsy sample was transferred to a 96-well plate containing 15 μL of 50 mM NaOH and 
heated at 98 °C for 2 min, cooled down to RT and neutralized with 1/10 volume of 1 M 
Tris-HCl pH 8.0. The supernatant was used for genotyping by PCR. Each larva was 
recovered in a single well of a 24-well plate with water E3 until 5 dpf. 
 
2.9.6 Caudal fin resection of transgenic zebrafish 
Transgenic zebrafish at different months of age were transiently anaesthetized with 
MESAB 1X for 2 min at RT. Fish were moved onto a plastic lid of a 10-cm dish and the 
distal portion of the caudal fin (2 mm) was cut with a sterile micro-scalpel. The tissue 
biopsy sample was placed in a 1.5 mL Eppendorf tube and stored at - 80 ˚C. The fish was 
recovered for 5 min in a small tank with water E3 prior to returning to its tank of origin. 
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2.9.7 Whole mount fish and haematoxylin and eosin staining 
Adult zebrafish were terminally anaesthetized with MESAB 1X for 5 min at RT and then 
placed on ice. Fish were fixed in 4 % paraformaldehyde for 24 h on a shaker at RT before 
proceeding with the deoxification process. After 5 min of washes with tap water, 
deoxification was initiated by incubation of the fish with I.E.D (Biocare Medical) for 4 h 
upon agitation at RT. Processing for paraffin embedding and preparation of H&E 10 μm 
sections were performed by the Cogentech S.c.a.r.l Tissue Processing Unit using standard 
protocols. Briefly, for H&E staining, sections were deparaffinized two times in xylene for 
10 min and re-hydrated in descending scale of EtOH (100 % to 70 %) for 5 min each. 
Sections were stained with Papanicolau haematoxylin solution for 30 sec, washed in tap 
H2O for 5 min and counterstained in eosin Y-solution for 8 sec. After washing in tap H2O 
for 5 min, sections were dehydrated through ascending scale of EtOH  (95 % to 100 %) for 
5 min each. Stained sections were cleared by two steps in xylene for 5 min and mounted 
with xylene based mounting medium. 
 
2.10 BIOINFORMATIC ANALYSIS 
The Ion Torrent™ NGS data were analyzed with the software developed by Dr. Silvestro 
Conticello (Istituto Toscano Tumori, Italy). Briefly, the BAM files generated by the Ion 
PGM™ and Ion Torrent™ Systems were converted to FASTQ format using SAMtools (Li 
et al., 2009) and an ad hoc Perl script. The reads were aligned to the reference sequences 
(mouse p53 and Gapdh mRNA; zebrafish p53 and β-actin mRNA) with MOSAIK (Lee et 
al., 2014) and the resulting files were sorted by start position. The analysis of the resulting 
SAM files was performed using a custom Perl script that trims the low quality ends of the 
reads and calculates for each SAM file the following information: 1) coverage for each 
position of the reference sequence; 2) correct coverage for each position of the reference 
sequence, considering a Phred quality score higher than a set threshold of 25. This 
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threshold represented the best trade-off to obtain a suitable number of reads while 
considering the quality of the sequences. 3) Count of the bases at each position of the 
reference sequence, taking into account the threshold Phred score. 
The scripts provided additional information, giving a quality overview of the run, such as 
1) distribution of the lengths of the reads; 2) distribution of the nucleotide changes from 
the reference sequence on the reads; and 4) statistical information on the frequency of the 
changes across the reads. This last point was measured to assess any technical bias. The 
frequency of mutations in each sample was calculated using two different scripts that set 
an a priori threshold for the mutation frequency for each position of the segment set as 
reference sequence. The overall mutation frequency is calculated taking into account the 
positions of the reference sequence in which there might have been the presence of 
polymorphisms in the original sample. 
The raw frequencies at each base were then processed as follows: only mutation 
frequencies that were above the minimum of 0.0005 were considered. Since the 
frequencies from each sample were derived from absolute number of reads, we adjusted 
the reads according to the highest SNPs frequency. This was based on the assumption that 
naturally occurring SNPs, which are part of the cell population, are independent of AID 
induced mutations and hence occurs at equal frequencies in all samples. To assess the 
significance of each mutation, any observed mutation frequency had to be larger than twice 
the combined frequencies of the other two samples: 
 
Frequencysample1 = frequencysample1 – 2*(frequencysample2 + frequencysample3) 
 
The expected frequency of mutations at dC/dG sites (EC:G) was calculated as follow: 
 
EC:G  = # of mutations% of dC/dG in mRNA sequence analyzed  
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The expected frequency of transitions at dC/dG sites (EC:G Ts) was calculated as follow:  
 
EC:G Ts = EC:G * Ts frequency (0.333) 
 
 The % of WRC present in the analyzed sequence was calculated prior to assess the 
expected frequency of mutations at WRC motifs (EWRC). 
 
WRC % = # WRC bases in mRNA analyzedtotal mRNA bases analyzed  % 
 
 
EWRC = (# of mutations) * (WRC %) 
 
The mutation rate for each run was calculated as follow: 
 
Mutation rate = absolute frequencysignificant muttotal mRNA bases analyzed  
 
The list of TP53 human mutations was generated using TP53 database MUT-2.0 (Soussi et 
al., 2010), and TP53 Mutation Assessor database (TP53 Mut Assessor) (Leroy et al., 
2013). 
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2.11 STATISTICAL ANALYSIS 
2.11.1 Student’s t-test 
Statistical analysis of normal distributed values was performed by two-tailed unpaired 
student’s t test. Differences were considered statistically significant if p value < 0.05. 
 
2.11.2 χ2 test 
Statistical analysis of table of contingency was measured using the χ2 test. Bonferroni 
correction was applied and differences were considered statistically significant if p value < 
0.016. 
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CHAPTER 3 – RESULTS 
 
3.1 TALE-AID INDUCES LOW FREQUENCY MUTAGENESIS IN VITRO 
To study the process of low-frequency mutagenesis during cancer induction at the trp53 
(p53) locus, we have generated new in vitro models by fusing the mouse DNA deaminase 
Aid to the sequence specific DNA binding protein TALE. 
 
3.1.1 Generation of mouse TALE-Aid fusion protein 
Three pairs (fused to a wild-type or mutant Aid protein) of TALEs (TALEa, TALEc, 
TALEe) were generated, each recognizing a unique sequence of 18 – 19 nucleotides within 
intron 4 of p53 (Figure 8A). The choice of target was made based on the following: 1) the 
majority of TP53 somatic mutations found in human tumors occur in the DBD; 2) targeting 
intron 4 allows us to observe mutations mostly in the DBD; 3) TALE is a large protein 
(120 kD), and by choosing the intron we limit the possibility of blocking the transcription 
machinery at the promoter or alter the coding sequence, and 4) previous work in our 
laboratory have shown that in vivo targeting of Aid to a specific locus induces DNA 
alterations of ~ 500 bp upstream and downstream of the DNA binding site (Franchini et al., 
2014). 
Mouse Aid cDNA was fused to the C-terminus of the TALE DNA binding domain 
followed by three Flag epitopes, with the expression driven by a CMV promoter (TALE-
Aid-wt-FL). A control construct was generated, where the same TALE was fused to a 
catalytic inactive form of Aid (E58Q) (TALE-Aid-mt-FL) (Figure 8B). 
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Figure 8: Targeting of p53 using TALE-Aid fusion proteins. 
A) Scheme of mouse p53 gene structure and TALE binding site (red triangle). p53 is composed of 11 exons, 
of which 10 are coding and colored according to the functional domains. Yellow: N-terminal domain; green: 
DNA binding domain; blue: C-terminal domain; grey: non coding region. The DNA binding domain is 
encoded beginning in exon 4 through exon 8, and TALE DNA binding protein targets 18-19 nt in the 4th 
intron. B) TALE-Aid-wt-FL (T-Aid-wt) fusion protein is composed of p53 sequence specific TALE (orange) 
fused to the mouse Aid cDNA (yellow) at the C-terminus, followed by three Flag (3FL) peptide as a tag 
(red). TALE-Aid-mt-FL (T-Aid-mt) fusion protein differs from Aid-wt in one amino acid (E58Q) in the 
deaminase domain. A CMV promoter drives protein expression. 
 
Given that the TALE itself is a very large protein (1200 aa), we wanted to ensure its full-
length mammalian expression. TALE-Aid-FL variants a, c, and e (Ta-Aid, Tc-Aid, Te-Aid, 
respectively) were transiently transfected into mouse NIH3T3 cells, and analyzed for 
protein expression after 24 hours by Western blot. Full-length protein was produced for all 
TALE constructs (Figure 9A). Importantly, there was no significant difference in 
expression between T-Aid-wt and T-Aid-mt constructs (Figure 9B). Based on this analysis, 
we decided to test Ta-Aid constructs for targeting and mutational activity. 
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Figure 9: T-Aid protein levels in NIH3T3 transfected cells. 
A) Immunoblot of protein lysates from NIH3T3 cells after 24 hours of transfection with T-Aid constructs (10 
µg). T-Aid-wt and T-Aid-mt protein levels were determined using anti-Flag antibody. B) Protein levels were 
quantified in arbitrary units (A.U.) with ImageLabTM software (Bio-Rad) and normalized according to 
Vinculin protein level. The graph represents three independent experiments with mean ± SEM. Statistical 
significance was calculated using Student’s t-test (* = p < 0.05, ** = p < 0.01, *** = p < 0.001 and n.s = not 
significant). 
 
3.1.2 TALE-Aid mutates the endogenous p53 locus in NIH3T3 cells 
In order to determine Aid’s ability to mutate the endogenous locus of p53, NIH3T3 cells 
were transiently co-transfected with Ta-Aid and EGFP reporter (pCDNA3-EGFP) 
plasmids. Western blot after 24 h confirmed Ta-Aid and EGFP protein expression, with 
Aid-wt and Aid-mt at similar levels (Figure 10).  
After 48 h we sorted GFP+ transfected cells and the efficiency was 36 % for Ta-Aid-wt and 
32 % for (Figure 11).  
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Figure 10: Ta-Aid and EGFP protein levels in NIH3T3 transfected cells. 
A) Immunoblot of protein lysates from NIH3T3 cells collected at 24 hours after co-transfection of Ta-Aid 
(10 µg) and EGFP (1 µg) vectors. Ta-Aid and EGFP protein levels were determined using anti-Flag and anti-
GFP antibodies, respectively. B) Protein levels were quantified in arbitrary units (A.U.) with ImageLabTM 
software (Bio-Rad) and normalized according to Tubulin protein level. The graph represents three 
independent experiments with mean ± SEM. 
 
 
 
Figure 11: FACS sorting of transfected NIH3T3 cells 
FACS sorting of transiently transfected NIH3T3 cells after 48 hours on a BD FACSAria™ III sorter for 
GFP+ cells. Numbers within the blot represents the frequency of GFP+ cells (purple dots) relative to GFP- 
cells (blue dots) in mock, Ta-Aid-wt and Ta-Aid-mt samples. 
 
To test the possibility that TALE proteins could block transcription at the target site 
through steric hindrance (Li et al., 2015), p53 mRNA levels were assessed by qRT-PCR 
after sorting of GFP+ cells.  Similar p53 expression levels were observed between mock-
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transfected cells and Ta-Aid transfected cells (Figure 12), suggesting that Ta-Aid proteins 
do not interfere with gene expression in our system. 
 
 
 
Figure 12: p53 mRNA levels in NIH3T3 transfected cells. 
A) Quantification by qRT-PCR of p53 transcripts in NIH3T3 cells after 48 hours of transfection with Ta-Aid 
constructs (10 µg) and sorting of GFP+ cells. Transcript Ct values were normalized to Gapdh mRNA 
abundance (ΔCt). The ΔΔCt values were calculated subtracting the ΔCt values of Ta-Aid transfected cells to 
the ΔCt values of the mock. The graph represents three independent experiments with mean ± SEM. 
Statistical significance was calculated using Student’s t-test (* = p < 0.05, ** = p < 0.01, *** = p < 0.001 and 
n.s = not significant). 
 
 
The mRNA was isolated and the p53 cDNA was amplified by high fidelity PCR and 
subjected to Ion Torrent™ NGS (Figure 13). 
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Figure 13: Mutational analysis of p53 in Ta-Aid transfected NIH3T3 cells. 
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A) Schematic representation of p53 gene with TALE target, mRNA product and protein structure (not in 
scale). Exons are colored according to the functional domains as described in Figure 8. B) p53 mutation 
frequency per base of NIH3T3 transfected cells assessed with Ion PGM™System. The x axis represents the 
position of 1047/1146 nucleotides analyzed of p53 mRNA, and the y axis represent the absolute frequency of 
the mutations observed. C) Significant mutations (based on the formulae described in section 2.10) are 
indicated with colored bars, according to the mutated nucleotide. (TA: transactivation domain; PXXP: 
proline rich domain; DBD: DNA binding domain; NLS: nuclear localization signal; OD: oligomerization 
domain; RD: regulatory domain). 
 
Two different Ion Torrent™ Systems were used for this analysis, Ion PGM™ and Ion 
Proton™, which differed in both the sensitivity and the DNA polymerase used for the 
sequencing reaction. Ion PGM™ System could read up to 108 bases per run and used a 
high-fidelity polymerase, while Ion Proton™ System had a higher throughput for each run 
(1010 bases), but used a lower fidelity polymerase.  
A total of ~ 6.2 – 7.5x105 reads/sample were generated with Ion PGM™ and ~ 1 – 1.5x107 
reads/sample with Ion Proton™, with an average read-length of ~ 200 bases. After the 
trimming of low-quality ends and the mapping to the reference sequence, the analysis was 
performed on ~ 6.1 – 7.3x105 reads/sample for Ion PGM™ and 0.8 – 1.2x107 reads/sample 
for Ion Proton™, with a mapping rate of 87 – 91 %. 
From this raw analysis possible PCR or sequencing errors needed to be excluded. Based on 
the formulae described in section 2.10, significant mutations for all three samples were 
calculated. In the Ta-Aid-wt sample, 27 mutated bases were identified with Ion PGM™ 
with a mutation rate of 3.9x10-5 per bp analyzed, and 31 with Ion Proton™ with a mutation 
rate of 6.5x10-5, with 26 in common. Neither mock nor Ta-Aid-mt samples showed any 
significant mutations (Figure 13C). To ensure accuracy of the Ion Torrent™ sequencing 
protocol and our analysis, p53 cDNA from the Ta-Aid-wt sample was re-amplified, 
subjected to a new release of Ion Torrent™ library prep and the Ion Proton™ run, and 28 
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mutations were observed (with a mutation rate 3.9x10-5), with 19 in common among the 
three runs. 
Of the 27 mutations observed in the Ion PGM™ run, 21 targeted dC and dG, with 13 being 
transitions and 7 occurring at WRC hotspot (A/T, A/G, C). The expected frequencies of 
dC/dG sites, transitions, and WRC were calculated and compared to the observed 
frequencies (Table 11). dC/dGs were targeted more often (56 % expected vs 77.7 % 
observed), leading to more transitions at dC/dG (33 % expected vs 86 % observed) and a 
different frequency of WRCs (11 % vs 26 %). The increase in transitions, dC targeting and 
WRCs was very suggestive of a DNA deaminase activity, with Ta-Aid recognizing and 
mutating the endogenous p53 locus. 
 
Table 11: p53 T-Aid-wt induced mutation analysis of NIH3T3 transfected cells. 
Total mutations: 27 Expected Observed 
dC/dG targets 15.1 21 
Ts at dC:dG 5 13 
WRC 3 7 
 
The table represents the expected frequencies of dC/dG targets, transitions (Ts) and WRC compared to the 
observed in Ion PGM™ System run. Calculations were made according to section 2.10. 
 
In Table 12, the individual mutations in p53 from Ta-Aid-wt transfected cells are listed. 
The majority of the mutations (23/37) were located in the DBD (amino acids 99 – 289), 
while the remaining were located at the N-terminus (8/37) and the oligomerization domain 
(6/37). In addition, 24 were missense mutations, 1 non-sense and 12 silent mutations. 
Some of these orthologous mutations were also conserved in human cancers, as analyzed 
in the TP53 mutation database (Leroy et al., 2013; Soussi et al., 2010). This included the 
C>T transition R279C (human R282W) in exon 8 that resides in a hot spot highly 
frequently mutated in human cancers (777 tumors), and leads to the complete protein 
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inactivation. In the same hot spot region two more mutations were conserved in human 
cancers, both leading to the inactivation of p53 protein: M243I (human M246I) was 
reported in 52 tumors and R264P (human R267P) was found in 25 tumors. Moreover, the 
R178C amino acid change in exon 5 (human R181C), arising from a C>T transition in a 
WRC motif, was observed in 38 tumors, with p53 activity being reduced, while W143* in 
exon 5 (human W146*), led to the translation of a truncated protein, with no functional 
activity left and was observed in 131 different cancers. These findings suggested that AID 
is targeting hotspot residues in human cancers, as it was already hypothesized (Lindley, 
2013). 
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Table 12: p53 mutations classification. 
 
List of all significant mutations from Figure 13. Exon, codon, amino acid substitution, transitions at dC/dG, 
WRC context and distance to TALE target are represented for each mutation. The list of orthologous human 
mutations found in cancer was generated with TP53 mutation database (Leroy et al., 2013; Soussi et al., 
2010), with the frequency, the predicted p53 activity, and the relevance to human cancers, shown. 
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Aside from mutations commonly found in human cancers, less frequent amino acidic 
changes were observed in the DBD. For example, N236S and R280S (human N239T and 
R283S respectively) were found at the hot spot region and are rarely reported in human 
cancers up to now, but lead to the p53 protein inactivation, affecting the p53 ability to bind 
the DNA. We did not score insertions/deletions, since the alignment algorithm of the raw 
Ion Torrent™ reads eliminated all insertion and deletion reads. This was done in part due 
to the inherit inaccuracy of the Ion Torrent™ System in misreading insertions and 
deletions. 
Analysis of the distance of the observed mutations from the TALE binding site identified 
mutations ~ 600 bp upstream and ~ 2 kb downstream of the genomic target site (Table 12). 
These findings suggested that, although Ta-Aid binds to a specific sequence of p53 more 
towards the N-terminus, the whole locus seemed accessible to Aid mutator activity. 
To evaluate the specificity of Ta-Aid, Gapdh mRNA was amplified and sequenced (Figure 
14). Applying the same criteria as for the p53 analysis, only one significant mutation was 
detected from the T-Aid-mt sample, and none in the other samples – leading to a mutation 
rate of 3.3x10-7 per bp (now defined as the technical limitation in this assay). In the past it 
has been speculated that Ion Torrent™ sequence analysis was not sufficient for mutation 
detection, but in our assay we could distinguish a mutation rate from Ta-Aid that was 100 
fold above technical error background, and 100 fold below that of SHM (Sale and 
Neuberger, 1998). 
Together these findings suggested that our in vitro approach led us to mutagenize the p53 
locus and identify, not only hotspot residues mutated by Aid in cancers, but also novel 
mutations that could be relevant for cancer progression.  
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Figure 14: Mutational analysis of Gapdh. 
A) Gapdh mutation frequency per base of NIH3T3 transfected cells is indicated with color bars according to 
the mutated nucleotide. The x axis represents the position of  804/1002 nucleotides analyzed of Gapdh 
mRNA and the y axis represents the absolute frequency of the mutations observed. B) Significant mutations 
(based on the formulae described in secion 2.10) are indicated with colored bars. 
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3.1.3 TALE-Aid soft-agar assay 
To evaluate if our mutations in p53 could have a positive effect on cellular transformation, 
an anchorage-independent growth soft agar assay was performed. NIH3T3 cells were 
transfected with all T-Aid pair constructs and 24 h later re-plated at the density of 103/well 
into agar medium. Cluster/colony formation was monitored for 4 weeks, and 8-cell clusters 
for each transfection were scored, with a slight increase in Tc-Aid-wt transfected cells 
compared to Tc-Aid-mt, but no significant increase compared to mock cells (Figure 15). 
Although there was an indication that Aid-wt induced a phenotypic change in the 
transfected cells, this was not significant. Given our mutation analysis result, it is likely 
that this assay would not have provided us with the proper frequency (both p53 alleles 
needed to be targeted) to observe any phenotypic changes; hence we also attempted other 
assays. 
 
 
 
Figure 15: T-Aid does not affect anchorage-independent growth of NIH3T3 cells. 
NIH3T3 cells were transfected with T-Aid constructs (10 µg) and at 24 h plated for anchorage independent 
growth. Colonies were counted after 4 weeks. Only 8-cell clusters were observed in the samples and are 
shown in the graph as number of 8-cell clusters/well of each sample, normalized to mock. The graph 
represents one experiment.  
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3.1.4 TALE-Aid induces p53-dependent loss of senescence in pMEFs 
To overcome the limitations of the NIH3T3 immortalized fibroblasts, we took advantage 
of a more suitable experimental system, consisting of primary mouse embryonic 
fibroblasts (pMEFs), carrying one p53 null allele. It is known that primary MEFs undergo 
stress-associated senescence after a limited number of passages in standard in vitro 
conditions (Parrinello et al., 2003). Mutations and inactivation of p53 can overcome the 
replication block, leading to immortalization (Harvey and Levine, 1991).  
To evaluate if the T-Aid low-frequency mutagenesis could affect cellular senescence, 
pMEFs were derived from p53+/- embryos (Jacks et al., 1994) at E12.5 – E13.5. Early 
passage (p 4) p53+/- pMEFs were transfected with Ta-Aid constructs and EGFP reporter 
plasmid, and full-length protein expression was analyzed after 24 h by immunoblotting 
(Figure 16). Ta-Aid constructs were less expressed when transiently transfected in pMEFs 
as compared to NIH3T3 cells, probably due to the difficulties we encountered in 
transfecting mouse primary cells. 
 
 
 
Figure 16: T-Aid and EGFP expression in transfected p53+/- pMEFs. 
A) Immunoblot of protein lysates from p53+/- pMEFs collected at 24 hours after co-transfection with Ta-Aid 
(2 µg) and EGFP (200 ng) vectors. Ta-Aid and EGFP protein levels were determined using anti-Flag and 
anti-GFP antibodies, respectively. B) Protein levels were quantified in arbitrary units (A.U.) with 
ImageLabTM software (Bio-Rad) and normalized according to Tubulin protein level. The graph represents one 
experiment. 
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After 72 h, GFP+ cells were sorted from Ta-Aid-wt (1.8 %) and Ta-Aid-mt (1.3 %) 
transfections (Figure 17), and re-plated at 300 cells/well. After 3 weeks 11 clones (9 % - 
from total well numbers) arising from Ta-Aid-wt transfected cells and 2 clones (2.4 %) 
from Ta-Aid-mt cells were scored, together with 21 clones (35 %) in the mock sample. 
 
 
 
Figure 17: FACS sorting of transfected p53+/- pMEFs. 
p53+/- pMEFs at passage 4 were transiently transfected with Ta-Aid and EGFP constructs and FACS sorted 
after 72 h on BD FACSAria™ III sorter for GFP+ cells. Numbers within the blot represents the frequency of 
GFP+ cells (purple dots) relative to GFP- cells (blue dots) in mock, Ta-Aid-wt and Ta-Aid-mt samples. 
 
Total RNA was extracted from each clone and p53 expression evaluated by RT-PCR. Only 
two clones from Ta-Aid-wt (#4 and #5) and one clone from the mock (#14) transfection 
expressed full-length p53 mRNA (Figure 18).  
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Figure 18: p53 expression of p53+/- pMEF transfected clones. 
Representative p53 expression of transiently transfected Ta-Aid-wt, Ta-Aid-mt p53+/- pMEFs and mock 
clones was monitored by RT-PCR of full-length p53 mRNA. Untreated pMEFs were used as positive 
control. Gapdh was amplified as loading control. 
 
From those clones that produced p53 mRNA, we sequenced the p53 cDNA. Ta-Aid-wt 
clones #4 and #5 contained a 10-nucleotide deletion at position 85, which was absent in the 
mock clones (Figure 19A). In silico analysis predicted the translation of a truncated protein 
of 46 amino acids as a result of the frame-shift deletion. This includes the very N-terminus 
of p53 protein, with only one transactivation domain expressed. Importantly, at the 5’ end 
of the deletion there was a WRC motif followed by a palindromic sequence forming a 
secondary structure (Figure 19B). These results suggested that Ta-Aid-wt deaminated the 
WRC sequence on ssDNA and the fragile structure downstream of the targeted dC formed 
a stem-loop resulting in a deletion, possibly via DNA polymerase slippage. 
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Figure 19: p53 cDNA sequencing results from transfected p53+/- pMEF clones. 
A) Sequencing chromatogram of untreated p53+/- pMEFs, Ta-Aid-wt clones #4 and #5. The deletion is 
highlighted with the red box and is present only in clones #4 and #5. B) Sequence of the deletion with 
schematic WRC motif highlighted at the 5’ end (orange box). The deletion is a palindromic sequence and can 
form a stem loop as shown in the picture above. Nucleotides position of p53 mRNA are shown at the bottom. 
 
In the remaining Ta-Aid-wt, Ta-Aid-mt and mock clones, genomic p53 was analyzed 
through a walking PCR approach (Figure 20A). The region spanning from exon 2 to exon 
9 of p53 wt allele was amplified and exon 2 – 7 were found deleted in all the T-Aid clones 
analyzed, with clones #4 and #5 serving as controls (Figure 20B). The PCR analysis 
showed a genomic band corresponding to exon 8 – 9, resulting from the amplification of 
the p53+/- targeted allele. These results suggested that there was the loss of the p53 second 
allele. The loss of the second allele of a tumor suppressor is a common event during cancer 
progression, called loss of heterozygosity (LOH), and could explain why clones escaped 
senescence. 
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Figure 20: p53 gDNA analysis of transiently transfected p53+/- pMEF clones. 
A) Schematic representation of p53 alleles in p53+/- pMEFs. In the recombined allele, a neomycin cassette 
replaces the region spanning from exon 2 to exon 6 (Jacks et al., 1994). Primer pairs (Af - Ar, Bf - Br, Cf - 
Cr, Df - Dr, Ef - Er) used for genomic amplification are depicted. B) Representative p53 genomic 
amplification of transiently transfected Ta-Aid-wt, Ta-Aid-mt and mock clones. Untreated pMEFs were used 
as positive control. 
 
PCR amplification of mock samples gDNA resulted in the deletion of intron 4 and possibly 
exon 5 (Figure 20B). Given that spontaneous p53 inactivation can occur in pMEFs leading 
to an immortalized phenotype, it is possible that mock clones underwent such an Aid-
independent event. Further experiments are needed to confirm our hypothesis. 
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 3.2 STUDY OF LOW FREQUENCY MUTAGENESIS INDUCED BY TALE-AID 
IN VIVO 
Aside from targeting p53 in cell lines, we aimed to generate a new in vivo cancer model for 
low frequency mutagenesis, either by transiently expressing TALE-AID in zebrafish 
embryos or by creating a transgenic zebrafish expressing TALE-AID. 
 
3.2.1 Generation of EGFP-TALE-AID fusion proteins 
Analogous to the mouse approach, the tp53 (p53) DNA binding domain of zebrafish wt 
strain (AB) was targeted. Zebrafish p53 shares 46 % homology with the mouse counterpart 
with the DBD more conserved (Cheng et al., 1997). Two TALEs (TALEg, TALEh) were 
designed to target a set of 19 nucleotides in intron 6 (Figure 21A). The choice of the target 
was based on: 1) the above listed assumptions for mouse targeting, 2) our data on the 
mouse cells that show how TALE-Aid can target large section of the p53 genome, 3) and 
the description of three p53 zebrafish mutants, tp53N168K and tp53I166T in exon 6 and 
tp53M214K in exon 7, leading to neoplasia (Berghmans et al., 2005; Parant et al., 2010). 
To visualize its expression during zebrafish embryo development, the N-terminus of the 
engineered TALE was fused to EGFP reporter protein, while the C-terminus was fused to 
human AID either wild type or the catalytic inactive form (E58Q). Expression of the 
EGFP-TALE-AID (EGFP-Tg-AID, EGFP-Th-AID) protein was driven by an EF1α 
promoter (Figure 21B).  
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Figure 21: Targeting of zebrafish p53 using EGFP-TALE-AID fusion proteins. 
A) Schematic of the genomic p53 locus in zebrafish. TALE binding site is indicated by the red triangle. 
Exons are colored according to the functional domains. Yellow: N-terminal domain; green: DNA binding 
domain; blue: C-terminal domain; grey: non coding region. The DNA binding domain (green) is encoded 
beginning in exon 4 through exon 8, and TALE DNA binding proteins target 19 nt in the 6th intron. B) 
EGFP-TALE-AIDwt (EGFP-T-AIDwt) fusion protein is composed of EGFP at the N-terminus fused to p53 
sequence-specific TALE (orange) followed by human AID cDNA (yellow) at the C-terminus. EGFP-TALE-
AIDmt (EGFP-T-AIDmt) fusion protein differs in one amino acid (E58Q) in the deaminase domain.  
An EF1 α promoter drives protein expression of both constructs. 
 
Prior to injecting the plasmid vector containing EGFP-T-AID constructs into zebrafish 
embryos, full-length expression was assessed in HEK 293T cell lines (Figure 22). EGFP 
expression was analyzed 24 h after transfection by fluorescence microscopy. EGFP-T-AID 
and EGFP-AID fusion proteins had reduced expression compared to EGFP alone (Figure 
22A). To ensure that the C-terminal AID was also expressed, immunoblot analysis on cell 
extracts confirmed equivalent protein expression across all TALE-AID fusion proteins 
(Figure 22B). 
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Figure 22: EGFP-T-AID expression in transfected HEK 293T cells. 
A) HEK 293T cell were transfected with EGFP expressing vector (pT2AL200R150), EGFP-AIDwt, and 
EGFP-T-AID constructs (2 µg), and analyzed after 24 h for EGFP expression by fluorescence microscopy. 
Representative images are shown. Scale bar 200 µm. B) Immunoblot of protein lysates from transfected HEK 
293T cells (24 h). EGFP-T-AID protein levels were determined using anti-AID antibody, and Vinculin was 
used as loading control. 
 
3.2.2 EGFP-TALE-AID is expressed in zebrafish embryos 
Fertilized eggs spawn by AB zebrafish strain were injected with EGFP-Tg-AID constructs 
together with Rhddext, and EGFP alone (pT2A200R150G) as positive control (Figure 23). 
Rhddext is a vital dye used to follow the injection’s outcome without interfering with 
embryo’s development. As shown in Figure 23, Rhddext expression was inconsistent in 
embryos analyzed at 24 hpf within the same injection (panel b’, c’ and d’), reflecting the 
intrinsic variability of the injection itself, which was also observed in EGFP expression 
(panel b”, c”, d”). Similar to the in vitro transfections, a decrease in EGFP expression was 
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observed in EGFP-Tg-AID compared to EGFP-only injected embryos. Once injected into 
fertilized one-cell stage embryo, expression in the developing embryo can be random, 
depending on the location of the insertion. EGFP injected embryos expressed EGFP in 
various tissues, including somites, eye and brain (panel b”’), while in EGFP-Tg-AIDwt 
injected embryos EGFP was detectable in the brain and in the yolk region (panel c”’). 
EGFP-Tg-AIDmt embryos expressed EGFP mainly in the eyes and the head (panel d”’). 
 
 
 
Figure 23: EGFP-T-AID expression in injected zebrafish embryos. 
Representative bright field and fluorescence images of embryos at 24 hpf, previously anaesthetized with 
Tricaine and mounted on methylcellulose 3 %. 200 – 300 embryos were co-injected with Rhddext (5 pg) and 
EGFP (pT2AL200R150G) (b, b’, b”, b”’), EGFP-Tg-AIDwt (c, c’, c”, c”’), and EGFP-Tg-AIDmt (d, d’, d”, 
d”’) (40 pg per plasmid). The control (AB) represents a non-injected embryo (a, a’, a”, a”’). Magnification 
22.5X. Scale bar 500 µm. 
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3.2.3 Embryos injected with EGFP-TALE-AIDwt exhibit developmental defects 
To test if TALE-AID fusion protein could alter embryonic development through p53 
mutagenesis, we monitored TALE-AID activity during embryogenesis. To this end, 24 hpf 
embryos injected with EGFP-Tg-AID and controls, EGFP-AIDwt or EGFP only, 
underwent morphological analysis. We used the 24 h end point because: 1) zygotic 
transcription starts only 3.5 hpf - at the mid-blastula transition when cell division becomes 
asynchronous (Kane and Kimmel, 1993); 2) there is an intrinsic mortality until 6 hpf due to 
the fertilization process which could bias the readout; 3) primary organogenesis and body 
axis start at 10 hpf, while at 24 hpf the circulation and fins appear, allowing the embryo to 
move; and 4) pigmentation, which complicates the morphological observations under the 
transmitted light, starts after 24 hpf (Kimmel et al., 1995). 
After removing dead embryos at 6 hpf, at 24 hpf we categorized the embryos into 4 groups 
according to their phenotype: normal, mild, severe and dead. Normal phenotype was 
assigned to embryos that resembled a non-injected AB embryo (Figure 24A panels a, b, c, 
d and Figure 23 panel a). Mild phenotype represented embryos with a defined anterior-
posterior axis, but short bodies, curved trunks and minor defects (panels a’, b’, c’, d’), 
while severe phenotype included embryos with problems since the gastrulation stage (6 
hpf), with a functional heart, but an indistinguishable body (panels a”, b”, c”, d”). 
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Figure 24: Post-injection developmental phenotypes. 
A) Representative bright field images of 24 hpf embryos injected with EGFP (a, a’, a”), EGFP-AIDwt (b, b’, 
b”), EGFP-Tg-AIDwt (c, c’, c”) and EGFP-Tg-AIDmt (d, d’, d”) (40 pg per plasmid) previously 
anaesthetized in Tricaine and mounted on methylcellulose 3 %. The developing embryos were separated into 
four groups according to their phenotype: normal (a, b, c, d), mild (a’, b’, c’, d’), severe (a”, b”, c”, d”), and 
dead (not shown). Magnification 40X. Scale bar 250 µm.  B) Representation of the observed frequencies of 
the phenotypes reported in Table 13. 
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Two independent injections were performed, and results are shown in Table 13. In one 
injection (#1), there was a significant increase in mild, severe, and dead embryos due to the 
presence by EGFP-Tg-AIDwt, compare to EGFP-Tg-AIDmt and EGFP-AID (Table 14). 
Furthermore, the difference between EGFP-Tg-AIDwt and EGFP-Tg-AIDmt injected 
embryos points towards the need of AID catalytic activity (Figure 24B). Un-injected AB 
embryos displayed normal developmental rates and none of the phenotypes described 
above was observed. These results suggested that TALE-AIDwt expression has an impact 
on zebrafish development, possibly via p53 mutations. However, we cannot exclude that 
TALE protein could act as roadblock and influence embryo’s development by altering p53 
mRNA production. 
 
Table 13: Frequency of phenotypes in 24 hpf injected embryos. 
Injection Construct Normal (%) Mild  (%) Severe (%) Death (%) N 
#1 
EGFP-AIDwt 75.51 11.56 9.52 3.40 147 
EGFP-Tg-AIDwt 44.85 12.50 27.21 15.44 136 
EGFP-Tg-AIDmt 82.16 7.04 3.76 7.04 213 
       
#2 
EGFP 89.71 6.86 2.29 1.14 175 
EGFP-Tg-AIDwt 84.49 5.31 4.49 5.71 245 
EGFP-Tg-AIDmt 65.79 14.91 12.28 7.02 114 
 
Frequency of the phenotypes observed in 2 independent injections (24 hpf). Injection #1 was performed with 
EGFP-AID as injection control (N = 147), EGFP-Tg-AIDwt (N = 136) and EGFP-Tg-AIDmt (N = 213). 
Injection #2 was performed with EGFP as injection control (N = 175), EGFP-Tg-AIDwt (N = 245) and 
EGFP-Tg-AIDmt (N = 114).  
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Table 14: Statistical analysis of phenotypes in 24 hpf injected embryos. 
Injection Pairwise comparison p-value χ 2 value d.f 
#1 
EGFP-AID vs EGFP-Tg-AIDwt 1.6x10-7 34.37 3 
EGFP-AID vs EGFP-Tg-AIDmt 0.026 9.295 3 
EGFP-Tg-AIDwt vs EGFP-Tg-AIDmt 3.8x10-13 60.85 3 
     
#2 
EGFP vs EGFP-Tg-AIDwt 0.052 7.723 3 
EGFP vs EGFP-Tg-AIDmt 1.7x10-5 27.34 3 
EGFP-Tg-AIDwt vs EGFP-Tg-AIDmt 2.6x10-4 19.05 3 
 
Statistical significance of observed phenotypes was calculated using χ2 test. Bonferroni correction was 
applied and significance was considered only if p-value < 0.016. (d.f = degree of freedom). 
 
3.2.4 TALE-AID mutagenesis in zebrafish embryos 
Using NIH3T3 cells we were able to demonstrate in vitro that targeting Aid to an 
endogenous locus induced mutations in p53. To determine the frequency of targeted 
mutations in an organism, a mutational analysis of the p53 locus on 24 hpf injected 
embryos was performed. 20 embryos with mild phenotype from EGFP-Tg-AIDwt and 
EGFP-Tg-AIDmt injections, as well as normal AB embryos, were subjected to RNA 
isolation, cDNA synthesis, PCR amplification and Ion Proton™ NGS. Raw data analysis 
was carried out as for the NIH3T3 data and 10 unique mutations in EGFP-Tg-AIDwt 
sample were found that were absent in EGFP-Tg-AIDmt and mock samples (Figure 25).  
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Figure 25: Mutational analysis of p53 in EGFP-T-AID injected embryos. 
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A) Schematic representation of zebrafish p53 gene with TALE target, mRNA product and protein structure. 
Exons are colored according to the functional domains as described in Figure 21 (not in scale). B) p53 
mutations frequency per base of 24 hpf embryos injected with EGFP-Tg-AIDwt, EGFP-Tg-AIDmt 
constructs and AB controls. The x axis represents the position of 1074/1110 nucleotides analyzed of p53 
mRNA and the y axis represents the absolute frequency of the mutations observed. C) Significant mutations 
are indicated with colored bars, according to the nucleotide. (TA: transactivation domain; PXXP: proline rich 
domain; DBD: DNA binding domain; NLS: nuclear localization signal; OD: oligomerization domain; RD: 
regulatory domain). 
 
Of the 10 mutations, 3 were found at WRC motifs and 1 was a transition at dC-dG. 
Mutations were equally distributed upstream and downstream of the TALE target, 
spanning from exon 4 to exon 11, with the distance from target to mutation being up to 4 
kb. Three orthologous mutations were found in human TP53 (Table 15).  
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Table 15: zebrafish p53 mutations classification. 
 
List of all significant mutations from Figure 25. Exons, codon, amino acid substitution, transitions at dC/dG, 
WRC context and distance to TALE target are represented for each mutation. The list of orthologous human 
mutations found in human cancers was generated with TP53 mutation database (Leroy et al., 2013; Soussi et 
al., 2010), with the frequency, the predicted p53 activity, and the relevance to human cancers, shown. 
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To ensure specificity of the targeting and the mutation approach, β-actin mRNA was 
amplified and sequenced. We were not able to score any significant mutation from three 
samples analyzed (not shown).  
These results suggested that EGFP-Tg-AIDwt induced low-frequency mutagenesis at the 
p53 locus of mild embryos. However, we could not establish a direct correlation between 
phenotype and mutation frequency. Although the mutation frequency in the NIH3T3 
targeting was significantly higher, the preliminary data from the zebrafish targeting is very 
encouraging and we are currently pursuing this approach more intently. 
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3.3 EGFP-TALE-AID TRANSGENIC ZEBRAFISH  
3.3.1 Generation of transgenic lines 
Aside from transiently mutating the endogenous p53 locus of zebrafish embryos, we 
generated transgenic lines expressing stably EGFP-T-AIDwt and the AIDmt control, to 
study the tumorigenic potential of AID-dependent p53 loss.  
To this end, we took advantage of the Tol2-mediated transposon host approach for plasmid 
integration into the genome (Urasaki et al., 2006). Here, a synthetic mRNA encoding the 
transposase and the transposon-donor containing plasmid are co-injected into fertilized 
eggs. The transposase protein catalyzes the excision of the transposon-like construct from 
the donor plasmid and induces its random integrations into the genome (Figure 26). The 
mRNA and the transposase protein gradually degrade and the Tol2 insertions become 
stable.  
 
Figure 26: Schematic representation of transgenesis in zebrafish. 
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Generation of a transgenic zebrafish using Tol2 transposon mediated approach. The synthetic transposase 
mRNA and a transposon donor plasmid (EGFP-T-AID vectors) containing two minimal Tol2 fragments are 
co-injected into zebrafish fertilized eggs. The Tol2 containing fragment is excised from the donor plasmid 
and integrated into the genome. The integration happens in the germ cells at the frequency of 50 – 70 %, and 
the resulting germ cells of the transposed fish are mosaic (founder). Crossing the founder with a wild type 
fish resulted in non-transgenic and transgenic heterozygous embryos with a variable frequency (3 to 100 %) 
(Urasaki et al., 2006).  
 
Zebrafish embryos are capable of independent feeding by 5 dpf, as the yolk supplies are 
largely depleted by the first week. EGFP-T-AID (wt and mt) constructs were microinjected 
together with transposase mRNA into AB fertilized eggs. From two independent 
microinjections with each construct (EGFP-Tg-AID and EGFP-Th-AID), non-fertilized 
eggs and dead embryos were removed and ~ 100 remaining larvae (6 dpf) per injection 
were raised to adulthood in the IFOM Zebrafish Unit aquarium. Only 10 to 30 fish per 
injection reached the adult stage (3 mpf) (Table 16), while in the non-injected AB embryos 
an intrinsic mortality of 30 – 40 % in the first three months was routinely observed.  
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Table 16: Germline transmission frequency of EGFP-TALE-AID injected zebrafish. 
Injection Construct (pg) N eggs 6 hpf 
N alive 
larvae 6 dpf 
N adult 
fish 
N bred 
fish 
N 
germline 
Germline 
% 
3.1 EGFP-Tg-AIDwt 40 130 100 15 8 2  
17.6 3.2 EGFP-Tg-AIDwt 30 150 100 22 9 1 
         
5.1 EGFP-Tg-AIDmt 40 100 80 30 5 1  
10 5.2 EGFP-Tg-AIDmt 30 110 80 25 5 0 
         
4.1 EGFP-Th-AIDwt 40 170 100 25 5 0  
18 7.1 EGFP-Th-AIDwt 30 110 70 15 6 2 
         
4.2 EGFP-Th-AIDmt 40 150 70 30 3 1 33.3 
7.2 EGFP-Th-AIDmt 30 110 60 15 3 2 
         
Total      44 9  
 
Two independent injections for each construct were performed. For each injection, the construct, the amount 
of injected plasmid (pg), the total number of eggs at 6 hpf and the total number of alive larvae at 6 dpf are 
indicated. The number of fish raised to adulthood, of fish outbred to AB fish and fish giving germline 
transmission are also reported, with the germline transmission frequency for each construct. 
 
A breeding program was initiated to select founder animals. Injected adult animals were 
crossed to AB fish and resulting F1 embryos were analyzed for EGFP expression under a 
fluorescence microscope and/or genotyped. Putative tg(EF1α-EGFP-T-AID) embryos 
were analyzed with fluorescence microscopy at 24 hpf, but expression was barely 
detectable. Confocal microscopy analysis was performed on single embryos and EGFP 
expression detected in different regions of the embryos, such as the eye, notochord and otic 
vesicle (Figure 27). 
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Figure 27: Tg(EF1α-EGFP-T-AID)  embryos express EGFP-TALE-AID protein. 
A) 24 hpf tg(EF1α-EGFP-T-AID) embryo was  anaesthetized and mounted in 1.2 % low-melting agarose in 
E3 water and EGFP expression was analyzed by confocal microscopy. Magnification 40X. Scale bar 250 µm. 
B) Confocal images of different anatomical part of a representative embryo: 1) eye (E), 2) otic vesicle (O.V) 
and 3) notochord (N). Magnification 40X. Scale bar 80 µm. 
 
Although the expression of the transgene could be verified, the weak EGFP signal limited 
the possibility of transgenic embryos screening based on EGFP expression.  
To overcome this limitation, we established a recently published fin-clip approach on alive 
larvae at 72 hpf for genotyping (Wilkinson et al., 2013). The larvae were temporally 
anaesthetized and the embryonic tail cleaved, followed by rapid genomic DNA extraction 
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and genotyping by PCR (Figure 28A). Transgene expression was confirmed on RNA 
extracted from total larvae at 5 dpf that were fin-clip positive (Figure 28B). 
 
 
 
Figure 28: EGFP-T-AID genotyping and mRNA expression of transgenic embryos. 
A) PCR amplification of AID transgene was performed on extracted DNA from fin-clip of 72 hpf larvae. 
Genomic p53 was amplified as loading control. Larva #4 has integrated EGFP-Tg-AIDwt transgene, while 
larvae #3 and #4 are positive for EGFP-Tg-AIDmt. AB larvae are used as negative controls, while pLS7129 
is amplified as positive control for the transgene presence.  B) EGFP-T-AID mRNA expression was 
determined by RT-PCR on mRNA extracted from representative fin-clipped larvae at 5 dpf. β-actin was 
amplified as loading control. 
 
As expected, the integration of the construct in the germ cell was very heterogeneous, 
ranging from 10 – 33 %, as summarized in Table 16. Moreover, germ cells of the founder 
fish are mosaic because of multiple insertions of the construct in the genome. Crossing 
founders with AB fish, the frequency of F1 transgenic embryos is not mendelian, but can 
vary from 3 % to 100 % (Urasaki et al., 2006). 
At least one founder for each transgenic line was identified, the F1 generation established 
and crossed to AB fish, where a mendelian segregation of the integrated transgene was 
observed.  
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3.3.2 Characterization of EGFP-TALE-AID transgenic animals 
Although the aim of my work is to generate a new animal model for neoplastic 
transformation, we also monitored the lifespan and fertility of our lines.  
 
3.3.2.1 Lifespan 
Under standard laboratory conditions, the zebrafish average lifespan is 24 – 36 months 
(Gerhard et al., 2002), yet some of our founder females from the EGFP-T-AIDwt line died 
after 9 to 13 months. Gross anatomical changes were not detected, and we are in the 
process of setting up a proper lifespan analysis. 
 
3.3.2.2 Fertility 
To determine the capacity of founder animals to induce spawning and produce fertilized 
eggs, transgenic females were mated to multiple AB males of similar age (to avoid the 
possibility of male-dependent fertility impairment). After 6 h of spawning period we 
scored three different types of eggs: fertilized, non-fertilized and dead (Figure 29).  
 
 
 
Figure 29: Fertilization success of tg(EF1α-EGFP-Tg-AID) females. 
Representation of the fertilization success of tg(EF1α-EGFP-Tg-AIDwt) compared tg(EF1α-EGFP-Tg-
AIDmt) founder females and AB controls from Table 15. Two independent breeding were set up for each 
female analyzed.  
 
  120 
Fertilized eggs were characterized by the presence of the germ ring, a typical feature of 6 
hpf stage. Non-fertilized eggs remained at one-cell stage, while dead eggs were made of 
apoptotic cells. Three tg(EF1α-EGFP-T-AIDwt) females, two tg(EF1α-EGFP-T-AIDmt) 
females and two AB females were induced to spawn in two independent breeding. 
Tg(EF1α-EGFP-T-AIDwt) animals showed a substantial increase in non-fertilized and 
dead eggs: females #1 and #3 produced 10 – 15 % of fertilized eggs compared to 80 – 100 
% of tg(EF1α-EGFP-Tg-AIDmt) and AB females. Interestingly, tg(EF1α-EGFP-Tg-
AIDwt) female #2 did not spawn any eggs in either experiment, even upon induction after 
manual squeezing (Table 17). 
 
Table 17: Frequency of fertilization success of tg(EF1α-EGFP-Tg-AID) females. 
 Fertilized % Non fertilized % Dead % N of eggs 
Breeding: A B A B A B A B 
AB #1 86.7 89.2 13.3 6.9 n.sp 3.8 98 130 
AB #2 92.1 59.0 7.9 41 n.sp n.sp 114 39 
         
EF1α-EGFP-Tg-AIDwt #1 n.sp 14.7 n.sp 42.7 n.sp 42.7 0 75 
EF1α-EGFP-Tg-AIDwt #2 n.sp n.sp n.sp n.sp n.sp n.sp 0 0 
EF1α-EGFP-Tg-AIDwt #3 2.9 10.8 91.7 84.9 n.sp 4.3 34 397 
         
EF1α-EGFP-Tg-AIDmt #1 100 82.4 n.sp 17.6 n.sp n.sp 48 17 
EF1α-EGFP-Tg-AIDmt #2 62.8 98.3 36 1.7 1.2 n.sp 325 291 
 
Frequency of fertilization success of tg(EF1α-EGFP-Tg-AID) females assessed in two independent breeding 
A and B (n.sp = non spawned eggs). Total number of eggs counted per breeding is reported. 
 
Although a number of factors could lead to such a phenotype, the significant difference 
with the AIDwt animals, led us to analyze this phenomena more precisely to possibly 
identify a problem in the reproductive system due to AID-induced damages. 
To begin the analysis of the female reproductive system, we initiated a time-course study 
at different months of age in the F1 generation (Figure 30A). Histological analysis 
performed on paraffin sections of tg(EF1α-EGFP-Tg-AIDwt) animals showed regions of 
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highly disorganized cells in the stroma surrounding the developing ovarian follicles 
(Figure 30B panels b, b’, b”) that were not detected in tg(EF1α-EGFP-Tg-AIDmt) (panels 
c, c’, c”) or AB controls (panels a, a’, a”). 
 
 
 
Figure 30: Histological analysis of transgenic females ovaries. 
Tg(EF1α-EGFP-Tg-AIDwt) and Tg(EF1α-EGFP-Tg-AIDmt) females were analyzed at 4 and 6 mpf for 
gross abnormalities. A) Sagittal section of H&E staining of an adult female (6 mpf), with highlighted in the 
black box the position of the ovaries. Magnification 7X. Scale bar 1.5 mm. B) Representative images of 
H&E staining of ovaries from AB (a, a’, a”), tg(EF1α-EGFP-Tg-AIDwt) (b, b’, b”) and tg(EF1α-EGFP-Tg-
AIDmt) (c, c’, c”) females at 6 mpf. Oocytes at different stages of development are represented: Eo = Early 
vitellogenic oocyte, Lv = Late vitellogenic oocyte, Mo = mature/spawning oocyte. The stroma is indicated by 
arrows. Magnification 4X, 10X and 20X. Scale bar 500 µm, 100 µm and 100 µm respectively. 
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The stroma is composed of a vascular connective tissue and forms a continuous layer over 
the neighboring ovarian follicles, called theca layer, while single follicles are surrounded 
by granulosa cells (Patiño, 2002). These fibrotic-like regions were observed with a 
frequency of 66.6 % at 4 mpf and 62.5 % at 6 mpf, while they were absent in animals at 12 
mpf both transgenic and controls (Table 18). 
 
Table 18: Pathological phenotypes in zebrafish females at different mpf. 
Genotype Sex Age (months) Phenotype 
AB Female 4 0/2 
tg(EF1α-EGFP-Tg-AIDwt) Female 4 2/3 (66.6 %) 
tg(EF1α-EGFP-Tg-AIDmt) Female 4 0/3 
    AB Female 6 0/2 
tg(EF1a-EGFP-Tg-AIDwt) Female 6 5/8 (62.5 %) 
tg(EF1α-EGFP-Tg-AIDmt) Female 6 0/1 
    
AB Female 12 0/3 
tg(EF1α-EGFP-Tg-AIDwt) Female 12 0/3 
tg(EF1α-EGFP-Tg-AIDmt) Female 12 0/2 
 
Tg(EF1α-EGFP-Tg-AID) females at different mpf were analyzed for abnormalities in the reproductive 
system. Frequency of fibrotic-like tissue is reported for experimental animals and related AB controls.
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3.4 GAL4/UAS MOUSE MODELS: A COMPLEMENTARY APPROACH FOR 
LOW FREQUENCY MUTAGENESIS  
So far, we have demonstrated that targeting TALE-Aid fusion protein to an endogenous 
locus in vitro, we could induce mutations at low frequency. Moreover, in the in vivo 
model, preliminary results suggested that TALE-AID could induce mutations at the p53 
locus, even if at significant lower frequency compared to the in vitro results. Our previous 
work demonstrated that Aid when fused to the Gal4 DNA binding domain retained the 
catalytic activity in vivo (Franchini et al., 2014). 
To study the process of low-frequency mutagenesis with Aid in vivo, we created another 
animal model using the Gal4/UAS approach to target Aid to our locus of interest in a 
transgenic mouse. We decided to generate two UAS knock-in mice to target p53 and Apc. 
Breeding Gal4-Aid mouse to the UAS knock-in mouse, Gal4-Aid could bind the UAS 
binding site and target our gene of interest, inducing low-frequency mutations. 
Gal4-Aid deamination activity was tested in vitro before creating a Gal4-Aid transgenic 
mouse. The Gal4 DNA binding domain was fused to wt mouse Aid cDNA - to generate 
Gal4-Aid fusion protein (Gal4-Aid-wt) and the deaminase activity of the fusion protein 
was determined using the Rif-mutagenesis assay in E. coli (Franchini et al., 2014). 
Two different transgenic mouse lines expressing either Gal4-Aid-wt or Gal4-Aid catalytic 
mutant (E58G) fusion proteins under the control of the CMV-promoter were generated 
(CMV-Gal4-Aid) (Franchini et al., 2014), and Gal4-Aid was identified to be ubiquitously 
expressed in various tissues in the adult by RT-PCR (Figure 31), confirming our previous 
results (Franchini et al., 2014). 
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Figure 31: Gal4-Aid expression in transgenic CMV-Gal4-Aid mice. 
Gal4-Aid expression in a representative transgenic CMV-Gal4-Aid-wt mouse and control (Ctr) at 3 months 
of age was monitored by RT-PCR. RNA samples were from lung, liver, kidney, and spleen. Gapdh was 
amplified as loading control. 
 
Gal4-Aid activity was demonstrated in vivo by using a demethylation assay: female CMV-
Gal4-Aid mice were bred to male mice harboring Gal4 binding sites in a methylated 
genomic locus (H19-DMR-UAS). Analysis of fetal liver samples and embryos showed that 
Gal4-Aid-wt could induced local-DNA demethylation (500 bp upstream / downstream of 
its binding site) near its targeted region, demonstrating that Gal4-Aid fusion can be used as 
a viable means for targeted DNA damage (Franchini et al., 2014). 
 
3.4.1 Generation of p53UAS/+ knock-in mouse 
To generate the p53UAS/+ knock-in mouse, we followed the above described strategy for 
TALE targeting, and three tandem UAS sites were inserted into intron 4 of p53. A classical 
targeting construct (pLS7070) was generated, where a neomycin (Neo) selection cassette 
was flanked by two loxP sites, imbedded within the homologous targeting sequence 
(Figure 32). 
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Figure 32: Strategy for the generation of p53UAS allele via homologous recombination. 
The targeting vector pLS7070 and the genomic organization of p53 is shown at the top. pLS7070 contains 
three tandem UAS sites fused to intron 4 of p53 and a Neo cassette flanked by two loxP sites, imbedded 
within the homologous targeting sequences. Theoretical crossover between endogenous p53 and the 
linearized vector is depicted by the crossed lines. After homologous recombination, the UAS sequence with 
the Neo cassette have been integrated in intron 4. The Neo cassette is removed by crossing the founder 
p53UASNeo mouse with a Deleter-Cre mouse. 
 
E14tg2α ES cells were electroporated with the linearized vector and resulting clones were 
analyzed by southern blot for homologous recombination events (Figure 33A). Of 570 
clones screened, only one had homologous recombined the targeting construct correctly 
(clone F41) (Figure 33B). 
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Figure 33: Southern blot analysis of electroporated ES cells with pLS7070. 
A) Diagram showing probe design for p53 targeting: digestion with Hind III and hybridization with 5’ 
genomic probe resulted in a fragment of 7 kb for endogenous wt allele and 4.5 kb for the knock-in allele. 
Hybridization with 3’ probe after EcoRV digestion results in a wt fragment of 4.6 kb and a recombined allele 
of 7.4 kb. B) ES cell DNA (3 μg) extracted from G418 resistant clones, was digested with Hind III, run on a 
0.8% agarose gel, blotted onto a nylon membrane and hybridized with 32P labeled 5’ probe. Clone F41 has 
correctly homologous recombined the vector into p53 gene. 
 
After karyotype analysis with 76 % of euploid metaphases, F41 clone was injected into 
C57BL/6J blastocysts that were then implanted into pseudo-pregnant CD1 females. The 
first injection (#1) resulted in no born pups, while the second injection (#2) gave birth to 
13 pups. Of these, one male chimera was found, with 45 % of agouti coat color. It was 
raised to adulthood and mated to Deleter-Cre (N = 4) or C57BL/6J (N = 2) females. All 
resulting pups (N = 146) had black coat color, with no germline transmission observed 
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(Table 19). For this reason, new injections will be done into C57BL/6J blastocysts to find 
new chimeras and to generate a Gal4-Aid/p53UAS/+ transgenic mouse. 
 
Table 19: p53UAS/+ knock-in ES cells injections and pups analyzed. 
Clone 
 
Karyotype 
 # injection 
N of 
pups 
N of 
chimera 
Sex 
 Chimera mated 
F41 76 % 1 0   Female ID N of pups 
Germline 
transmission 
  2 13 1 M Del-Cre #1 24 0 
      Del-Cre #2 25 0 
      Del-Cre #3 28 0 
      Del-Cre #4 25 0 
      C57BL/6J #1 34 0 
      C57BL/6J #2 10 0 
Total   13 1  6 146 0 
 
The table summarizes two injections performed with the p53UAS/+ recombined clone F41 into C57BL/6J 
blastocysts. The number of pups, number of chimeras and sex for each injection are represented. One 
chimera was found and was mated to different females. Breeding, number of pups and germline transmission 
are also summarized here. 
 
3.4.2 Generation of ApcUAS/+ knock-in mouse 
To generate ApcUAS/+ knock-in mouse, we decided to target intron 15 of Apc (Figure 34), 
based on the fact that the majority of APC mutations found in human colon cancers are 
situated in exon 16 (Mutation Cluster Region) (Cottrell et al., 1992).  
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Figure 34: Strategy for the generation of ApcUAS allele via homologous recombination. 
The targeting vector pLS7106 and the genomic organization of Apc are shown at the top. pLS7106 contains 
three tandem UAS sites fused to intron 15 of Apc and a Neo cassette flanked by two loxP sites, imbedded 
within the homologous targeting sequences. Theoretical crossover between endogenous Apc and the 
linearized vector is depicted by the crossed lines. After homologous recombination, the UAS sequence with 
the Neo Cassette have been integrated in intron 15. The Neo cassette is removed by crossing the founder 
ApcUASNeo mouse with a Deleter-Cre mouse. 
 
As already described for p53UAS/+ knock-in mouse generation, a classical targeting 
construct was made (pLS7106) and electroporated into E14tg2α ES cells. Of 480 clones 
screened by southern blot analysis (Figure 35A), only one had recombined correctly the 
vector into Apc gene (Figure 35B). The positive ES clone will be subjected to karyotype 
analysis and injected into C57BL/6J blastocyst to generate chimeras. 
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Figure 35: Southern blot analysis of electroporated ES cells with pLS7106. 
A) Diagram showing probe design for Apc targeting: digestion with Psi I and Cla I and hybridization with 5’ 
genomic probe resulted in a fragment of 10.5 kb for endogenous wt allele and 5.6 kb for the knock-in allele. 
Hybridization with 3’ probe after Bgl II digestion results in a wt fragment of 4.9 kb and a recombined allele 
of 7.3 kb. B) ES cell DNA (3 μg) extracted from G418 resistant clones was digested with Bgl II, run on a 0.8 
% agarose gel, blotted onto a nylon membrane and hybridized with 32P labeled 5‘ probe. Clone C39 has 
correctly homologous recombined the vector into Apc gene. 
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CHAPTER 4 - DISCUSSION 
 
Cancer is the second most common cause of death after cardiovascular diseases and 
accounts for 1 in 4 deaths in Europe (Ferlay et al., 2013). Cancer is an evolutionary 
process, characterized by the accumulation of mutations in individual cells over time, 
resulting in uncontrolled growth and spread of abnormal cells. 78 % of all cancers 
diagnosed are in patients of 55 years old or older. Given the long time (more that 20 years) 
until a tumor is clinically detected, it is reasonable to think that thousands of mutations 
have accumulated in tumor cells from the time an individual is exposed to a DNA 
damaging source to the clinical detection of the tumor. Importantly, animal models have 
contributed to the understanding of the molecular and cellular mechanisms underlying 
tumor initiation and progression, but the majority of these approaches have not lead to full 
disease recapitulation. 
In the present study, I developed a new model that mimics the process of mutation 
accumulation during human cancer development and progression. Fusing the natural 
mutator AID to sequence-specific binding proteins, I could demonstrate AID-induced low 
frequency mutagenesis at the p53 locus of mouse cell lines and full organisms, thereby 
affecting cellular integrity and moreover inducing cellular transformation. 
 
4.1 ESTABLISHMENT OF A NEW TOOL FOR LOW-FREQUENCY 
MUTAGENESIS IN VITRO 
To study the process of low-frequency mutagenesis in vitro, the mouse DNA deaminase 
Aid was fused to a sequence specific TALE, customized to target intron 4 of the p53 locus. 
TP53 is the most frequent mutated gene in human cancers, with the majority of the 
  131 
mutations affecting the DBD. The choice of intron 4 ensured the T-Aid to target mostly the 
p53 DBD, which is encoded by exon 4 – 8, a genomic region of 2.4 kb. 
The ability of Aid to retain the catalytic activity when fused to a DNA binding protein was 
demonstrated in a previous work of our laboratory, where Gal4-Aid mediated the 
demethylation of ~ 1.2 kb region of the mouse H19 locus (Franchini et al., 2014). 
The choice of the TALE as the tool to target Aid at the p53 locus was made based on the 
following considerations: 1) in contrast to the Gal4 binding protein that needs the specific 
UAS sequence to bind DNA (Ornitz et al., 1991), TALE can recognize any sequence of 
interest with high specificity and high affinity, customizing its central amino acid repeats 
responsible for DNA binding (Boch et al., 2009; Meckler et al., 2013; Moscou and 
Bogdanove, 2009); 2) this tool facilitates the targeting of specific endogenous loci both in 
cell lines (Hockemeyer et al., 2011; Maeder et al., 2013b) and organisms (Sung et al., 
2013; Zhang et al., 2014); and 3) the engineering of TALE proteins is cost and time-
effective as compared to ZFP, where imperfections of the modularity with particular 
domains lead to the lack of high-affinity binding to all DNA triplets. 
Aid was chosen to induce local DNA lesions at the p53 locus because, aside from its 
central role in the immune system, is capable of mutating DNA in almost any living cells. 
If deregulated, it was shown to induce mutations in key tumor suppressor genes, including 
TP53 (Beale et al., 2004; Lindley, 2013), leading to cancer progression (Matsumoto et al., 
2007; Shimizu et al., 2014), and the C>T DNA deaminase mutational signature was 
identified in many cancers (Burns et al., 2013b; Nik-Zainal et al., 2012). Furthermore, the 
deamination of cytosine to uracil is a natural occurring event reverted via physiological 
pathways, such as BER and MMR. Importantly, previous work demonstrated that the 
error-prone MMR is activated in non-B cells upon AID-damage (Pena-Diaz et al., 2012) 
and (Incorvaia E., and Petersen-Mahrt S.K. unpublished), possibly explaining the 
detrimental effect of AID expression outside the immune system. 
  132 
Thus, the creation of TALE-Aid fusion proteins provides a novel tool in the field of 
genome editing, that enables the targeting of a natural mutagen to an endogenous locus, 
inducing local DNA lesions and cellular transformation, leading to the possibility of 
uncovering novel mutations important for human cancers.  
TALE proteins, if targeted to a transcribed region, can block transcription at the target site 
through steric hindrance (Li et al., 2015). Similar levels of p53 transcript were observed in 
mock and TALE-Aid transfected NIH3T3 cells (Figure 12), suggesting that transcriptional 
elongation of RNAPII was not affected by TALE proteins in our in vitro system.  
Transient transfections of NIH3T3 cells with T-Aid and deep sequencing of the p53 
mRNA after 48 h, revealed the presence of 37 unique point mutations in T-Aid sample 
(Figure 13C). Importantly, this analysis was carried out with two recently developed NGS 
complementary approaches, Ion PGM™ and Ion Proton™ Systems. Although they 
differed in the throughput per run and the fidelity of the DNA polymerase used, both were 
able to detect 19 common mutations in the transfected NIH3T3 cells (Table 12), with a 
frequency of ~ 3.9 – 6.5x10-5 mutations per bp. Our results are in agreement with previous 
work that estimated a mutation rate of ~ 1– 90x10-5 mutations per bp in non-Ig genes, with 
the mutation rate in the oncogene BCL-6 of 9x10-4 (Liu et al., 2008), much lower compared 
to the mutation rate at the Ig locus during SHM (~10-3 mutations per bp) (Sale and 
Neuberger, 1998). This difference is explained by the fact that non-Ig genes are protected 
from SHM by high fidelity repair of AID-dependent damage. 
The types of mutations that AID induces on ssDNA have been extensively studied, which 
include transitions at dC in the sequence context of WRC (W= dA or dT; R= dA or dG) 
(Beale et al., 2004; Morgan et al., 2004; Pham et al., 2003). Importantly, in our analysis 
mutagenesis at dC/dG sites was observed (77.7 %) more often than expected (56 %), as 
were transitions at dC/dGs (86 % observed vs 33 % expected) and WRC (26 % observed 
vs 11 % expected) (Table 11), indicating that T-Aid functions at the p53 locus.  
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The majority of the mutations found in our mutational analysis of p53 mRNA were located 
in the DBD (23/37) (Table 12), with the remaining distributed in the N-terminus and the 
oligomerization domain. The spectrum of p53 mutations can be explained by the previous 
findings that the DBD resides in the fragile central region of p53, where each residue can 
be found mutated at least once in each human cancer, while the N- and C-termini are less 
sensitive to amino acids substitution (Kato et al., 2003; Soussi et al., 2010). Importantly, 
some of the mutations discovered in our analysis were conserved across human cancers as 
analyzed in the TP53 mutation database (Edlund et al., 2012; Soussi et al., 2010) (e.g. 
R279C, M243I), suggesting that AID can target and mutate hotspot residues in human 
cancers. Our hypothesis is supported by several studies showing a C>T transition pattern 
of p53 mutations in human cancers (Beale et al., 2004; Lindley, 2013; Shimizu et al., 
2014). The mutations observed in our study were not situated in PTMs sites affecting p53 
binding to its partners (Meek and Anderson, 2009), but could impair the binding to DNA, 
or p53 tetramerization, thus affecting the overall function. Aside from these frequently 
observed mutations, other altered amino acids were observed in our analysis and were 
rarely or never found in human cancers (e.g. N236S and R280S), underling the importance 
of our approach in defining new mutations possibly relevant for cancer progression. 
In our previous work, Aid fused to the DNA binding domain of Gal4, was shown to 
mediate demethylation ~ 500 bp upstream / downstream of its original target site in the 
H19 locus of mice (Franchini et al., 2014). Importantly, our positional analysis identified 
mutations ~ 600 bp upstream and ~ 2 kb downstream of the genomic target site, 
highlighting the ability of Aid to deaminate DNA at long distance from its initial target 
site, which in our case spans the majority of the locus.  
Although our analysis indicated that T-Aid is able to induce mutations in the p53 locus at 
relevant sites affecting p53 activity, when we tested the effect of T-Aid on cellular 
transformation by soft-agar assay, we could not observe any significant increase in 
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transformed clones (Figure 15). A possible explanation could be that the low frequency 
rate of mutations observed in our experiment was not sufficient to cause cellular 
transformation, suggesting that only one allele was targeted. To circumvent this possible 
problem, we determined the ability of p53+/- pMEFs that have been transiently transfected 
with T-Aid to undergo cellular senescence. Explanted MEFs initially continue to replicate 
in vitro, but then rapidly undergo stress-associated senescence due to in vitro conditions, 
especially oxidative stress caused by supraphysiological levels of O2 supplied during 
standard culturing conditions (Parrinello et al., 2003). However, if the p53 pathway is 
damaged, MEFs can overcome this replication block, leading to gradual outgrowth of an 
immortalized population (Harvey and Levine, 1991). Our preliminary results showed a 
total of 11 clones (9 %) arising from p53+/- pMEFs transfected with T-Aid-wt and 2 clones 
(2.4 %) from p53+/- pMEFs transfected with T-Aid-mt. Of the wt clones, only two were 
expressing p53 mRNA (Figure 18). Importantly, these two clones contained a 10 bp-
deletion in exon 3 that was predicted to form a truncated protein of 46 amino acids, with 
only the transactivation domain included. At the 5’ end of this deletion a WRC motif was 
followed by a palindromic sequence forming a secondary structure (Figure 19). We 
hypothesize that T-Aid in p53+/- pMEFs deaminated the cytosine at the WRC on ssDNA 
and the fragile structure downstream of the lesion formed a stem-loop. The deletion 
occurred probably as the result of DNA polymerase slippage during replication. Future 
experiments will be important to confirm our findings. 
Overall, we have established a novel system to study the low-frequency mutagenesis in 
cancer genes in vitro, with the possibility of uncovering novel important mutations. 
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4.2 TALE-AID INDUCED LOW FREQUENCY MUTAGENESIS IN ZEBRAFISH 
EMBRYOS 
To study the process of low-frequency mutagenesis in a living organism, we expressed 
EGFP-T-AID fusion proteins in zebrafish embryos, aimed at targeting intron 6 of p53. In 
recent years, zebrafish have become an established animal model for human diseases, 
including cancer. To test if EGFP-T-AID could alter p53 expression possibly leading to 
developmental defects, EGFP-T-AID was monitored in the developing embryos, that were 
categorized 24 h after injection according to their phenotype: normal, mild, severe and 
dead (Figure 24). A significant increase of mild, severe and dead embryos due to EGFP-T-
AIDwt expression was observed in one injection, but another injection did not show any 
differences (Table 14). These opposing results might be explained by two different 
hypothesis, 1) TALE-AID mutates p53, or 2) TALE physically acts as a roadblock for p53 
transcription (Li et al., 2015), both leading to p53-dependent developmental defects. P53 is 
expressed early during zebrafish development, with maternal p53 highly and ubiquitously 
expressed at 1 hpf, while at the pharyngula stage (24 – 48 hpf) p53 is predominantly 
expressed in the head region (Cheng et al., 1997; Thisse et al., 2000). Several studies 
conducted in animal models reported that p53 has other functions above its fundamental 
role in the induction of apoptosis and growth arrest. For instance, in zebrafish embryos, the 
expression of a p53 isoform Δ113p53, but not wild type p53, was shown to arrest the 
development of the digestive tract at 3 dpf (Chen et al., 2005). In mice, p53-/- female 
embryos exhibit significant developmental abnormalities, including profound neural-tube 
defects associated with overgrowth of neural tissues and craniofacial malformations, 
leading to frequent (23 %) embryonic lethality (Armstrong et al., 1995; Sah et al., 1995). 
In addition, p53-deficient Xenopus laevis embryos show inhibition of mesodermal 
differentiation and severe gastrulation defects (Cordenonsi et al., 2003). Importantly, 
increased p53 levels due to the disruption of Mdm2, lead to embryonic developmental 
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defects both in mouse and zebrafish causing lethality (Jones et al., 1995; Montes de Oca 
Luna et al., 1995; Thisse et al., 2000). 
To test our first hypothesis, a mutational analysis on injected embryos exhibiting the mild 
phenotype at 24 hpf was performed. Ion Proton™ NGS analysis revealed 10 unique 
mutations in embryos transiently injected with EGFP-T-AID embryos (Figure 25). Of 
these mutations, 3 were identified at WRC motif and 1 was a transition at dC/dG. 
Importantly, mutations spanned from exon 4 to exon 11, with a distance of up to 4 kb from 
the TALE target site. Based on these results it is possible that EGFP-T-AID induced low-
frequency mutagenesis at the p53 locus in mild embryos, but we cannot establish a direct 
correlation between phenotype and mutation frequency. It will be interesting to test our 
second hypothesis, if the TALE on its own can physically alter p53 expression, leading to 
embryonic developmental impairment.  
 
4.3 PHENOTYPIC ANALYSIS OF TALE-AID ZEBRAFISH LINES 
To study the tumorigenic potential of AID-induced mutagenesis, we generated a zebrafish 
line stably expressing EGFP-T-AID using the Tol2-mediated transposon host approach. 
The lack of efficient offspring generation (Table 16) could be due to p53-dependent 
developmental defects, as already hypothesized above. However, we cannot exclude the 
involvement of other factors, such as food up-take, slight changes in the environmental 
water (pH), and other environmental stress. 
Genomic analysis of F1 putative positive embryos revealed that the integration of the 
construct into the germ cell was heterogeneous (10 – 33 %) - as expected (Urasaki et al., 
2006) (Table 16), and at least one founder fish for each aimed transgenic line was 
identified. When we initiated a breeding program with female founders to establish the 
transgenic F1 generation, we observed a strong increase of non-fertilized and dead eggs in 
tg(EF1α-EGFP-Tg-AIDwt) animals compared to tg(EF1α-EGFP-Tg-AIDmt) and AB 
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females (Table 17). It is known from previous work that p53 is important for maternal 
fertility in mammals, by regulating the expression of the leukemia inhibitory factor (LIF), a 
cytokine crucial for blastocyst implantation. Loss of p53 in female mice leads to a decrease 
in fertility, due to the inefficient implantation (Hu et al., 2007), while in humans a common 
coding SNP at codon 72 results in either arginine (R72) or proline (P72), with the P72 
allele associated with implantation defects in women (Kang et al., 2009; Kay et al., 2006). 
In three p53 zebrafish mutants described so far (tp53N168K, tp53M214K and tp53I166T) normal 
fertility was observed (Berghmans et al., 2005; Parant et al., 2010). Although zebrafish 
fertilization takes place ex utero, and many external factors could eventually influence this 
process (e.g. environmental water temperature and pH), we hypothesized that EGFP-T-
AID induced alterations in p53, leading to impaired spawning of mature oocytes. In 
agreement with these findings, the histological analysis of the F1 reproductive system of 
tg(EF1α-EGFP-Tg-AIDwt) females revealed an atypical stromal structure, with 
disorganized and fibrotic-like tissue surrounding the developing ovarian follicles (Figure 
30). These results let us speculate that the impairment in spawning fertilized eggs is 
correlated to the pathological features observed in the reproductive organ. In support of 
this hypothesis, several studies showed that apoptosis plays an important role in the 
maturation of testes and ovaries in mammals and fish. During gonadal development in 
juvenile zebrafish (20 dpf), all individuals harbor undifferentiated ovary-like gonads 
(juvenile hermaphroditism) (Takahashi, 1977). In male zebrafish, oocytes disappear from 
the gonads by p53-mediated apoptosis between 21 – 25 dpf and spermatocytes develop 
(Rodriguez-Mari et al., 2010; Uchida et al., 2002), while in females, a programmed loss of 
oocytes occurs during ovarian development, where apoptotic cells are observed in the 
stromal tissue neighboring the developing oocytes by 40 dpf (Uchida et al., 2002). 
Moreover, during atresia of the pre-ovulatory follicles, hypertrophy and hyperplasia of the 
granulosa and theca cells within the stromal tissue are observed, followed by invasion and 
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absorption of the degenerated oocyte (Thome et al., 2009; Üçüncü and C ̧akıcı, 2009). 
Mature oocytes that escape atresia are extruded from the surrounding follicle cells 
(ovulation) and ready to spawn, with the stromal tissue undergoing structural changes to 
allow for the oocyte release (Patiño, 2002). Although many factors are involved in this 
process, including hormones (Chiang et al., 2001; Piferrer, 2001) and environmental stress 
(elevated water temperature) (Abozaid et al., 2012), I hypothesize that EGFP-T-AID 
dependent deregulated expression of p53 could alter a) the apoptotic process during 
ovarian maturation, leading to the production of dead and aberrant eggs, b) hyperplasia of 
the connective tissue. Indeed, these structural changes could cause the retention of the 
mature eggs during spawning, a process observed several times in our fertility analysis 
(Table 17). Based on the previous p53 zebrafish models that develop sarcomas in the 
abdomen, the eye and the flank with variable penetrance (Berghmans et al., 2005; Parant et 
al., 2010), I can also hypothesize that the hyperplastic connective tissue observed in 
tg(EF1α-EGFP-Tg-AIDwt) females are derived from a pre-neoplastic lesion. However, 
given that none of the females analyzed at 12 mpf (0/3) developed the transformed-like 
phenotype in the ovaries (Table 18), further analysis on a larger cohort of animals should 
be performed to confirm our hypothesis.  
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4.4 FUTURE PLANS 
4.4.1 Low frequency mutagenesis in vitro 
In this study, I was able to develop a new tool based on TALE-Aid ability to target and 
mutate with low frequency the p53 locus in cell lines. Aside from TALE-Aid fusion 
protein, we have created dCas9-Aid-wt and mt fusion proteins and validated Aid activity 
with the Rif-mutagenesis assay in E. coli. We designed three different gRNAs to target 
intron 4 of mouse p53, and to further validate our results obtained with TALE-Aid, I will 
transfect the NIH3T3 cells with dCas9-Aid and perform a mutational analysis with Ion 
Torrent™ NGS. To assess the specific binding of our fusion proteins to the p53 locus, I 
will perform a Chromatin Immunoproecipitation (ChIP) on NIH3T3 cells transfected with 
TALE-Aid and dCas9-Aid. Considering the simplicity of the CRISPR/Cas9 system as 
compared to the TALE system, I will extend this study to other tumor suppressor genes, 
creating a library of gRNA targeted to multiple loci and to human cell lines. 
 
4.4.2 Low frequency mutagenesis in zebrafish embryos 
I have shown that EGFP-T-AID is able to target the p53 locus of zebrafish embryos 
causing developmental defects in the first 24 hpf. However, the mutation frequency 
observed in the embryos was significantly lowered compared to targeting the p53 locus in 
the murine NIH3T3 cells. To better understand this process, I will inject AB fertilized eggs 
with EGFP-T-AID and I will perform a mutational analysis on mild and severe phenotype 
embryos after 24 hpf. Moreover, to understand if the TALE protein can induce a 
transcriptional alteration of p53, I will inject fertilized eggs with EGFP-TALE construct 
and p53 expression of both EGFP-T-AID and EGFP-TALE expressing embryos will be 
evaluated by RT-qPCR. To further analyze p53-mediated activity, I will treat EGFP-T-
AID injected embryos with γ radiation at 24 hpf and evaluate their apoptotic response by 
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TUNEL assay at 30 hpf. If p53 retains its wild type activity, irradiation will result in 
massive apoptosis. On the contrary, if EGFP-T-AID embryos express a mutant p53, a 
block in the apoptotic response will be observed.  
 
4.4.3 Low frequency mutagenesis in trangenic zebrafish lines 
In this study I have established a new zebrafish transgenic line tg(EF1α-EGFP-Tg-AIDwt), 
with ovarian maturation defects. To make our histological analysis more significant, I will 
increase the number of analyzed animals and include other time points. In particular, 
considering that ovarian maturation starts at ~ 1 mpf, female will be sacrificed to analyze 
the phenotypic changes during early development. To further understand if the phenotype I 
observed is gender-specific, I will extend the histologic analysis to adult males. Moreover, 
because we observed a shorter lifespan in some of our founder animals, I will assess a 
lifespan analysis increasing the number of animals. 
To better understand the role of p53 in our transgenic animals, I will evaluate p53 mRNA 
and protein expression in the reproductive system of tg(EF1α-EGFP-Tg-AID) females, and 
perform a mutation analysis on the pathological tissue biopsy. In addition, pathological 
tissues will be analyzed for proliferation markers, such as PCNA or KI67. Moreover, to 
assess if EGFP-T-AID is able to accelerate the process of neoplastic transformation, I will 
cross tg(EF1α-EGFP-Tg-AIDwt) animals with p53 mutant animals (p53M214K/+ and 
p53I166T/+), and  monitor tumor formation and tumor onset. 
 
4.4.4 A mouse model of Aid-induced low frequency mutagenesis 
I have previously demonstrated that T-Aid is capable of mutating an endogenous locus 
both in cell lines and in a living organism. Moreover, our previous findings of Gal4-
Aid/H19UAS animal model confirm that Aid fused to a DNA binding protein retains the 
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catalytic activity in mice. Due to unknown reasons, we have previously failed in the 
establishment of a p53 UAS/+ transgenic line and subsequently of the Gal4-Aid/p53 UAS/+ 
transgenic animals.  
Considering our mutational analysis in vitro, I would like to generate T-Aid transgenic 
mice, with T-Aid targeted to the p53 locus. To overcome the limitation of only one allele 
being targeted, this mouse will be crossed to p53+/- mice. I will start to monitor for tumor 
formation at different time points. Based on the tumor spectra present in p53-/- mice, I 
expect to observe a variety of tumors in T-Aid mice, such as lymphomas and sarcomas that 
will be characterized by immunohistochemistry and FACS analysis, and sequenced to find 
new/known mutations in p53. In addition, blood samples will be collected at different time 
points and NGS analysis will be performed to find p53 mutations during neoplastic 
transformation prior to full tumor formation. It was recently shown in humans, that 
circulating tumor DNA is found in patient’s blood stream prior to the clinical detection of 
the tumor (Forshew et al., 2012). The analysis on circulating tumor DNA in our models 
will allow us to follow mutation accumulation due to Aid activity.  
In parallel, I would like to generate dCas9-AID transgenic animals, which will allow us to 
target many loci, using different gRNAs.  
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